Targeting histone deacetylases for the treatment of immune, endocrine and metabolic disorders

Endocrine, Metabolic and Immune Disorders - Drug Targets

Volumn 9, Issue 1, 2009, Pages 84-107

  Lawless, M W ^a,b   Norris, S ^b   O'Byrne, K J ^b   Gray, S G ^b  

^a MATER MISERICORDIAE UNIVERSITY HOSPITAL   (Ireland)

^b TRINITY COLLEGE DUBLIN   (Ireland)

Author keywords

Breast; Chaperone; Diabetes; Histone deacetylase; Lupus; Multiple sclerosis; Pancreas

Indexed keywords

4 [N (2 HYDROXYETHYL) N [2 (3 INDOLYL)ETHYL]AMINOMETHYL]CINNAMOHYDROXAMIC ACID; 4 N ACETYLDINALINE; 4 PHENYLBUTYRIC ACID; 5 AZA 2' DEOXYCYTIDINE; ALPHA INTERFERON; ANTINEOPLASTIC AGENT; B LYMPHOCYTE INDUCED MATURATION PROTEIN 1; DAXX PROTEIN; DNA METHYLTRANSFERASE INHIBITOR; EPIRUBICIN; FLAVOPIRIDOL; FLUOROURACIL; GEMCITABINE; HISTONE ACETYLTRANSFERASE; HISTONE DEACETYLASE; HISTONE DEACETYLASE INHIBITOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; N (2 AMINOPHENYL) 4 (3 PYRIDINYLMETHOXYCARBONYLAMINOMETHYL)BENZAMIDE; PACLITAXEL; ROMIDEPSIN; SK 7041; TAMOXIFEN; TRANSCRIPTION FACTOR FOXP3; TRASTUZUMAB; TRICHOSTATIN A; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALPROIC ACID; VATALANIB; VORINOSTAT; ENZYME INHIBITOR;

ACUTE GRANULOCYTIC LEUKEMIA; ADVANCED CANCER; BLADDER CANCER; BREAST CANCER; CELL PROTECTION; CLINICAL TRIAL; COLORECTAL CANCER; CUTANEOUS T CELL LYMPHOMA; CYSTIC FIBROSIS; DIABETES MELLITUS; DISEASE MODEL; DRUG MECHANISM; DRUG POTENTIATION; DRUG TARGETING; EMBRYONIC STEM CELL; ENDOCRINE DISEASE; ENDOPLASMIC RETICULUM STRESS; ENZYME ACTIVITY; GLIOMA; HEAD AND NECK CANCER; HEMATOLOGIC MALIGNANCY; HUMAN; HUNTINGTON CHOREA; IMMUNE SYSTEM; IMMUNOPATHOLOGY; INFLAMMATION; KIDNEY CARCINOMA; LARGE CELL LYMPHOMA; LEUKEMIA; LUNG CANCER; LUNG NON SMALL CELL CANCER; MELANOMA; MESOTHELIOMA; METABOLIC DISORDER; MULTIPLE MYELOMA; MULTIPLE SCLEROSIS; MYELODYSPLASTIC SYNDROME; NEUROENDOCRINE TUMOR; NONHUMAN; OBESITY; OVARY CARCINOMA; PANCREAS ADENOCARCINOMA; PANCREAS CANCER; PANCREAS ISLET BETA CELL; RECURRENT CANCER; REVIEW; SOLID TUMOR; SPINAL MUSCULAR ATROPHY; SYSTEMIC LUPUS ERYTHEMATOSUS; T CELL LYMPHOMA; ANIMAL; BREAST TUMOR; DRUG ANTAGONISM; ENDOPLASMIC RETICULUM; METABOLISM; PANCREAS TUMOR; PHYSIOLOGY;

ANIMALS; BREAST NEOPLASMS; DIABETES MELLITUS; ENDOPLASMIC RETICULUM; ENZYME INHIBITORS; HISTONE DEACETYLASES; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MULTIPLE SCLEROSIS; NF-KAPPA B; PANCREATIC NEOPLASMS;

EID: 65549130132     PISSN: 18715303     EISSN: None     Source Type: Journal    
DOI: 10.2174/187153009787582441     Document Type: Review

References (384)

1. Gray, S.G. and Ekström, T.J. (2001) The human histone deacetylase family. Exp. Cell Res., 262(2), 75-83.
2. Perwez H.S. and Harris, C.C. (2007) Inflammation and cancer: an ancient link with novel potentials. Int. J. Cancer, 121(11), 2373-2380.
3. Karin, M. (2006) Nuclear factor-kappaB in cancer development and progression. Nature, 441(7092), 431-436.
4. Qatanani, M. and Lazar, M.A. (2007) Mechanisms of obesity-associated insulin resistance: many choices on the menu. Genes Dev., 21(12), 1443-1455.
5. Esiri, M.M. (2007) The interplay between inflammation and neurodegeneration in CNS disease. J. Neuroimmunol., 184(1-2), 4-16.
6. Moenner, M.; Pluquet, O.; Bouchecareilh, M. and Chevet, E. (2007) Integrated endoplasmic reticulum stress responses in cancer. Cancer Res., 67(22), 10631-10634.
7. Eizirik, D.L.; Cardozo, A.K. and Cnop, M. (2008) The role for endoplasmic reticulum stress in diabetes mellitus. Endocr. Rev., 29(1), 42-61.
8. Uehara, T. (2007) Accumulation of misfolded protein through nitrosative stress linked to neurodegenerative disorders. Antioxid. Redox Signal., 9(5), 597-601.
9. Wei, H.; Kim, S.J.; Zhang, Z.; Tsai, P.C.; Wisniewski, K.E. and Mukherjee, A.B. (2008) ER and oxidative stresses are common mediators of apoptosis in both neurodegenerative and non-neurodegenerative lysosomal storage disorders and are alleviated by chemical chaperones. Hum. Mol. Genet., 17(4), 469-477.
10. Gerritsen, M.E.; Williams, A.J.; Neish, A.S.; Moore, S.; Shi, Y. and Collins, T. (1997) CREB-binding protein/p300 are transcriptional co-activators of p65. Proc. Natl. Acad. Sci. USA, 94(7), 2927-2932.
11. Perkins, N.D.; Felzien, L.K.; Betts, J.C.; Leung, K.; Beach, D.H. and Nabel, G.J. (1997) Regulation of NF-kappaB by cyclin-dependent kinases associated with the p300 coactivator. Science, 275(5299), 523-527.
12. Wadgaonkar, R.; Phelps, K.M.; Haque, Z.; Williams, A.J.; Silverman, E.S. and Collins, T. (1999) CREB-binding protein is a nuclear integrator of nuclear factor-kappaB and p53 signaling. J. Biol. Chem., 274(4), 1879-1882.
13. Na, S.Y.; Lee, S.K.; Han, S.J.; Choi, H.S.; Im, S.Y. and Lee, J.W. (1998) Steroid receptor coactivator-1 interacts with the p50 subunit and coactivates nuclear factor kappaB-mediated transactivations. J. Biol. Chem., 273(18), 10831-10834.
14. Ashburner, B.P.; Westerheide, S.D. and Baldwin, A.S.Jr. (2001) The p65 (RelA) subunit of NF-kappaB interacts with the histone deacetylase (HDAC) corepressors HDAC1 and HDAC2 to negatively regulate gene expression. Mol. Cell. Biol., 21(20), 7065-7077.
15. Yeung, F.; Hoberg, J.E.; Ramsey, C.S.; Keller, M.D.; Jones, D.R.; Frye, R.A. and Mayo, M.W. (2004) Modulation of NF-kappaB-dependent transcription and cell survival by the SIRT1 deacetylase. EMBO J., 23(12), 2369-2380.
16. Hoberg, J.E.; Popko, A.E.; Ramsey, C.S. and Mayo, M.W. (2006) IkappaB kinase alpha-mediated derepression of SMRT potentiates acetylation of RelA/p65 by p300. Mol. Cell. Biol., 26(2), 457-471.
17. Hoberg, J.E.; Yeung, F. and Mayo, M.W. (2004) SMRT derepression by the IkappaB kinase alpha: a prerequisite to NF-kappaB transcription and survival. Mol. Cell, 16(2), 245-255.
18. Park, J.; Lee, J.H.; La, M.; Jang, M.J.; Chae, G.W.; Kim, S.B.; Tak, H.; Jung, Y.; Byun, B.; Ahn, J.K. and Joe, C.O. (2007) Inhibition of NF-kappaB acetylation and its transcriptional activity by Daxx. J. Mol. Biol., 368(2), 388-397.
19. Hollenbach, A.D.; McPherson, C.J.; Mientjes, E.J.; Iyengar, R. and Grosveld, G. (2002) Daxx and histone deacetylase II associate with chromatin through an interaction with core histones and the chromatin-associated protein Dek. J. Cell. Sci., 115(Pt 16), 3319-3330.
20. Kuo, H.Y.; Chang, C.C.; Jeng, J.C.; Hu, H.M.; Lin, D.Y.; Maul, G.G.; Kwok, R.P. and Shih, H.M. (2005) SUMO modification negatively modulates the transcriptional activity of CREB-binding protein via the recruitment of Daxx. Proc. Natl. Acad. Sci. USA, 102(47), 16973-16978.
21. Esposito, K.; Nappo, F.; Giugliano, F.; Di Palo, C.; Ciotola, M.; Barbieri, M.; Paolisso, G. and Giugliano, D. (2003) Cytokine milieu tends toward inflammation in type 2 diabetes. Diabetes Care, 26(5), 1647.
22. Dandona, P.; Aljada, A.; Chaudhuri, A. and Mohanty, P. (2004) Endothelial dysfunction, inflammation and diabetes. Rev. Endocr. Metab. Disord., 5(3), 189-197.
23. Dandona, P.; Aljada, A. and Bandyopadhyay, A. (2004) Inflammation: the link between insulin resistance, obesity and diabetes. Trends Immunol., 25(1), 4-7.
24. Vanden Berghe, W.; De Bosscher, K.; Boone, E.; Plaisance, S. and Haegeman, G. (1999) The nuclear factor-kappa B engages CBP/p300 and histone acetyltransferase activity for transcriptional activation of the interleukin-6 gene promoter. J. Biol. Chem., 274(45), 32091-32098.
25. Liu, Y.; Smith, P.W. and Jones, D.R. (2006) Breast cancer metastasis suppressor 1 functions as a corepressor by enhancing histone deacetylase 1-mediated deacetylation of RelA/p65 and promoting apoptosis. Mol. Cell. Biol., 26(23), 8683-8696.
26. Gao, F.; Cheng, J.; Shi, T. and Yeh, E.T. (2006) Neddylation of a breast cancer-associated protein recruits a class III histone deacetylase that represses NFkappaB-dependent transcription. Nat. Cell Biol., 8(10), 1171-1177.
27. Li, B.; Samanta, A.; Song, X.; Iacono, K.T.; Bembas, K.; Tao, R.; Basu, S.; Riley, J.L.; Hancock, W.W.; Shen, Y.; Saouaf, S.J. and Greene, M.I. (2007) FOXP3 interactions with histone acetyltransferase and class II histone deacetylases are required for repression. Proc. Natl. Acad. Sci. USA, 104(11), 4571-4576.
28. Bettelli, E.; Dastrange, M. and Oukka, M. (2005) Foxp3 interacts with nuclear factor of activated T cells and NF-kappa B to repress cytokine gene expression and effector functions of T helper cells. Proc. Natl. Acad. Sci. USA, 102(14), 5138-5143.
29. Kwon, H.K.; So, J.S.; Lee, C.G.; Sahoo, A.; Yi, H.J.; Park, J.N.; Lim, S.Y.; Hwang, K.C.; Jun, C.D.; Chun, J.S. and Im, S.H. (2008) Foxp3 induces IL-4 gene silencing by affecting nuclear translocation of NFkappaB and chromatin structure. Mol. Immunol., 45(11), 3205-3212.
30. Rutkowski, D.T. and Kaufman, R.J. (2004) A trip to the ER: coping with stress. Trends Cell Biol., 14(1), 20-28.
31. Hebert, D.N. and Molinari, M. (2007) In and out of the ER: protein folding, quality control, degradation, and related human diseases. Physiol. Rev., 87(4), 1377-1408.
32. Rapoport, T.A. (2007) Protein translocation across the eukaryotic endoplasmic reticulum and bacterial plasma membranes. Nature, 450(7170), 663-669.
33. Lai, E.; Teodoro, T. and Volchuk, A. (2007) Endoplasmic reticulum stress: signaling the unfolded protein response. Physiology (Bethesda), 22(3), 193-201.
34. Caruso, M.E. and Chevet, E. (2007) Systems biology of the endoplasmic reticulum stress response. Subcell. Biochem., 43, 277-298.
35. Ron, D. and Walter, P. (2007) Signal integration in the endoplasmic reticulum unfolded protein response. Nat. Rev. Mol. Cell Biol., 8(7), 519-529.
36. Pahl, H.L. and Baeuerle, P.A. (1997) The ER-overload response: activation of NF-kappa B. Trends Biochem. Sci., 22(2), 63-67.
37. Xu, C.; Bailly-Maitre, B. and Reed, J.C. (2005) Endoplasmic reticulum stress: cell life and death decisions. J. Clin. Invest., 115(10), 2656-2664.
38. Rao, R.V.; Ellerby, H.M. and Bredesen, D.E. (2004) Coupling endoplasmic reticulum stress to the cell death program. Cell Death Differ., 11(4), 372-380.
39. Bardag-Gorce, F.; Dedes, J.; French, B.A.; Oliva, J.V.; Li, J. and French, S.W. (2007) Mallory body formation is associated with epigenetic phenotypic change in hepatocytes in vivo. Exp. Mol. Pathol., 83(2), 160-168.
40. Hanada, S.; Harada, M.; Kumemura, H.; Bishr Omary, M.; Koga, H.; Kawaguchi, T.; Taniguchi, E.; Yoshida, T.; Hisamoto, T.; Yanagimoto, C.; Maeyama, M.; Ueno, T. and Sata, M. (2007) Oxidative stress induces the endoplasmic reticulum stress and facilitates inclusion formation in cultured cells. J. Hepatol., 47(1), 93-102.
41. Ohoka, N.; Hattori, T.; Kitagawa, M.; Onozaki, K. and Hayashi, H. (2007) Critical and Functional Regulation of CHOP (C/EBP Homologous Protein) through the N-terminal Portion. J. Biol. Chem., 282(49), 35687-35694.
42. Baumeister, P.; Luo, S.; Skarnes, W.C.; Sui, G.; Seto, E.; Shi, Y. and Lee, A.S. (2005) Endoplasmic reticulum stress induction of the Grp78/BiP promoter: activating mechanisms mediated by YY1 and its interactive chromatin modifiers. Mol. Cell. Biol., 25(11), 4529-4540.
43. Donati, G.; Imbriano, C. and Mantovani, R. (2006) Dynamic recruitment of transcription factors and epigenetic changes on the ER stress response gene promoters. Nucleic Acids Res., 34(10), 3116-3127.
44. Doody, G.M.; Stephenson, S. and Tooze, R.M. (2006) BLIMP-1 is a target of cellular stress and downstream of the unfolded protein response. Eur. J. Immunol., 36(6), 1572-1582.
45. Yu, J.; Angelin-Duclos, C.; Greenwood, J.; Liao, J. and Calame, K. (2000) Transcriptional repression by blimp-1 (PRDI-BF1) involves recruitment of histone deacetylase. Mol. Cell. Biol., 20(7), 2592-2603.
46. Rubenstein, R.C. and Zeitlin, P.L. (2000) Sodium 4-phenylbutyrate downregulates Hsc70: implications for intracellular trafficking of DeltaF508-CFTR. Am. J. Physiol. Cell Physiol., 278(2), C259-267.
47. Burrows, J.A.; Willis, L.K. and Perlmutter, D.H. (2000) Chemical chaperones mediate increased secretion of mutant alpha 1-antitrypsin (alpha 1-AT) Z: A potential pharmacological strategy for prevention of liver injury and emphysema in alpha 1-AT deficiency. Proc. Natl. Acad. Sci. USA, 97(4), 1796-1801.
48. Qi, X.; Hosoi, T.; Okuma, Y.; Kaneko, M. and Nomura, Y. (2004) Sodium 4-phenylbutyrate protects against cerebral ischemic injury. Mol. Pharmacol., 66(4), 899-908.
49. Vilatoba, M.; Eckstein, C.; Bilbao, G.; Smyth, C.A.; Jenkins, S.; Thompson, J.A.; Eckhoff, D.E. and Contreras, J.L. (2005) Sodium 4-phenylbutyrate protects against liver ischemia reperfusion injury by inhibition of endoplasmic reticulum-stress mediated apoptosis. Surgery, 138(2), 342-351.
50. Mulhern, M.L.; Madson, C.J.; Kador, P.F.; Randazzo, J. and Shinohara, T. (2007) Cellular osmolytes reduce lens epithelial cell death and alleviate cataract formation in galactosemic rats. Mol. Vis., 131397-1405.
51. Kubota, K.; Niinuma, Y.; Kaneko, M.; Okuma, Y.; Sugai, M.; Omura, T.; Uesugi, M.; Uehara, T.; Hosoi, T. and Nomura, Y. (2006) Suppressive effects of 4-phenylbutyrate on the aggregation of Pael receptors and endoplasmic reticulum stress. J. Neurochem., 97(5), 1259-1268.
52. Bonapace, G.; Waheed, A.; Shah, G.N. and Sly, W.S. (2004) Chemical chaperones protect from effects of apoptosis-inducing mutation in carbonic anhydrase IV identified in retinitis pigmentosa 17. Proc. Natl. Acad. Sci. USA, 101(33), 12300-12305.
53. Yam, G.H.; Gaplovska-Kysela, K.; Zuber, C. and Roth, J. (2007) Sodium 4-phenylbutyrate acts as a chemical chaperone on misfolded myocilin to rescue cells from endoplasmic reticulum stress and apoptosis. Invest. Ophthalmol. Vis. Sci., 48(4), 1683-1690.
54. Vij, N.; Fang, S. and Zeitlin, P.L. (2006) Selective inhibition of endoplasmic reticulum-associated degradation rescues DeltaF508-cystic fibrosis transmembrane regulator and suppresses interleukin-8 levels: therapeutic implications. J. Biol. Chem., 281(25), 17369-17378.
55. Ozcan, U.; Yilmaz, E.; Ozcan, L.; Furuhashi, M.; Vaillancourt, E.; Smith, R.O.; Gorgun, C.Z. and Hotamisligil, G.S. (2006) Chemical chaperones reduce ER stress and restore glucose homeostasis in a mouse model of type 2 diabetes. Science, 313(5790), 1137-1140.
56. de Almeida, S.F.; Picarote, G.; Fleming, J.V.; Carmo-Fonseca, M.; Azevedo, J.E. and de Sousa, M. (2007) Chemical chaperones reduce endoplasmic reticulum stress and prevent mutant HFE aggregate formation. J. Biol. Chem., 282(38), 27905-27912.
57. Wang, J.F.; Bown, C. and Young, L.T. (1999) Differential display PCR reveals novel targets for the mood-stabilizing drug valproate including the molecular chaperone GRP78. Mol. Pharmacol., 55(3), 521-527.
58. Bown, C.D.; Wang, J.F. and Young, L.T. (2000) Increased expression of endoplasmic reticulum stress proteins following chronic valproate treatment of rat C6 glioma cells. Neuropharmacology, 39(11), 2162-2169.
59. Chen, B.; Wang, J.F. and Young, L.T. (2000) Chronic valproate treatment increases expression of endoplasmic reticulum stress proteins in the rat cerebral cortex and hippocampus. Biol. Psychiatry, 48(7), 658-664.
60. Shao, L.; Sun, X.; Xu, L.; Young, L.T. and Wang, J.F. (2006) Mood stabilizing drug lithium increases expression of endoplasmic reticulum stress proteins in primary cultured rat cerebral cortical cells. Life Sci., 78(12), 1317-1323.
61. Wang, J.F.; Azzam, J.E. and Young, L.T. (2003) Valproate inhibits oxidative damage to lipid and protein in primary cultured rat cerebrocortical cells. Neuroscience, 116(2), 485-489.
62. Shao, L.; Young, L.T. and Wang, J.F. (2005) Chronic treatment with mood stabilizers lithium and valproate prevents excitotoxicity by inhibiting oxidative stress in rat cerebral cortical cells. Biol. Psychiatry, 58(11), 879-884.
63. Cui, J.; Shao, L.; Young, L.T. and Wang, J.F. (2007) Role of glutathione in neuroprotective effects of mood stabilizing drugs lithium and valproate. Neuroscience, 144(4), 1447-1453.
64. Iguchi, H.; Imura, G.; Toh, Y. and Ogata, Y. (2000) Expression of MTA1, a metastasis-associated gene with histone deacetylase activity in pancreatic cancer. Int. J. Oncol., 16(6), 1211-1214.
65. Xue, Y.; Wong, J.; Moreno, G.T.; Young, M.K.; Cote, J. and Wang, W. (1998) NURD, a novel complex with both ATP-dependent chromatin-remodeling and histone deacetylase activities. Mol. Cell, 2(6), 851-861.
66. Hofer, M.D.; Menke, A.; Genze, F.; Gierschik, P. and Giehl, K. (2004) Expression of MTA1 promotes motility and invasiveness of PANC-1 pancreatic carcinoma cells. Br. J. Cancer, 90(2), 455-462.
67. Miyake, K.; Yoshizumi, T.; Imura, S.; Sugimoto, K.; Batmunkh, E.; Kanemura, H.; Morine, Y. and Shimada, M. (2008) Expression of hypoxia-inducible factor-1alpha, histone deacetylase 1, and metastasis-associated protein 1 in pancreatic carcinoma: correlation with poor prognosis with possible regulation. Pancreas, 36(3), e1-9.
68. Nakagawa, M.; Oda, Y.; Eguchi, T.; Aishima, S.; Yao, T.; Hosoi, F.; Basaki, Y.; Ono, M.; Kuwano, M.; Tanaka, M. and Tsuneyoshi, M. (2007) Expression profile of class I histone deacetylases in human cancer tissues. Oncol. Rep., 18(4), 769-774.
69. Ouaissi, M.; Cabral, S.; Tavares, J.; Cordeiro da Silva, A.; Mathieu-Daude, F.; Mas, E.; Bernard, J.; Sastre, B.; Lombardo, D. and Ouaissi, A. (2007) Histone deacetylase (HDAC) encoding gene expression in pancreatic cancer cell lines and cell sensitivity to HDAC inhibitors. Cancer Biol. Ther., 7(4), 523-531.
70. Saito, A.; Yamashita, T.; Mariko, Y.; Nosaka, Y.; Tsuchiya, K.; Ando, T.; Suzuki, T.; Tsuruo, T. and Nakanishi, O. (1999) A synthetic inhibitor of histone deacetylase, MS-27-275, with marked in vivo antitumor activity against human tumors. Proc. Natl. Acad. Sci. USA, 96(8), 4592-4597.
71. Donadelli, M.; Costanzo, C.; Faggioli, L.; Scupoli, M.T.; Moore, P.S.; Bassi, C.; Scarpa, A. and Palmieri, M. (2003) an inhibitor of histone deacetylases, strongly suppresses growth of pancreatic adenocarcinoma cells. Mol. Carcinog., 38(2), 59-69.
72. Moore, P.S.; Barbi, S.; Donadelli, M.; Costanzo, C.; Bassi, C.; Palmieri, M. and Scarpa, A. (2004) Gene expression profiling after treatment with the histone deacetylase inhibitor trichostatin A reveals altered expression of both pro- and anti-apoptotic genes in pancreatic adenocarcinoma cells. Biochim. Biophys. Acta., 1693(3), 167-176.
73. Sato, N.; Ohta, T.; Kitagawa, H.; Kayahara, M.; Ninomiya, I.; Fushida, S.; Fujimura, T.; Nishimura, G.; Shimizu, K. and Miwa, K. (2004) FR901228, a novel histone deacetylase inhibitor, induces cell cycle arrest and subsequent apoptosis in refractory human pancreatic cancer cells. Int. J. Oncol., 24(3), 679-685.
74. Ryu, J.K.; Lee, W.J.; Lee, K.H.; Hwang, J.H.; Kim, Y.T.; Yoon, Y.B. and Kim, C.Y. (2006) SK-7041, a new histone deacetylase inhibitor, induces G2-M cell cycle arrest and apoptosis in pancreatic cancer cell lines. Cancer Lett., 237(1), 143-154.
75. Piacentini, P.; Donadelli, M.; Costanzo, C.; Moore, P.S.; Palmieri, M. and Scarpa, A. (2006) Trichostatin A enhances the response of chemotherapeutic agents in inhibiting pancreatic cancer cell proliferation. Virchows Arch., 448(6), 797-804.
76. Arnold, N.B.; Arkus, N.; Gunn, J. and Korc, M. (2007) The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces growth inhibition and enhances gemcitabine-induced cell death in pancreatic cancer. Clin. Cancer Res., 13(1), 18-26.
77. Gahr, S.; Ocker, M.; Ganslmayer, M.; Zopf, S.; Okamoto, K.; Hartl, A.; Leitner, S.; Hahn, E.G. and Herold, C. (2007) The combination of the histone-deacetylase inhibitor trichostatin A and gemcitabine induces inhibition of proliferation and increased apoptosis in pancreatic carcinoma cells. Int. J. Oncol., 31(3), 567-576.
78. Donadelli, M.; Costanzo, C.; Beghelli, S.; Scupoli, M.T.; Dandrea, M.; Bonora, A.; Piacentini, P.; Budillon, A.; Caraglia, M.; Scarpa, A. and Palmieri, M. (2007) Synergistic inhibition of pancreatic adenocarcinoma cell growth by trichostatin A and gemcitabine. Biochim. Biophys. Acta, 1773(7), 1095-1106.
79. Neureiter, D.; Zopf, S.; Leu, T.; Dietze, O.; Hauser-Kronberger, C.; Hahn, E.G.; Herold, C. and Ocker, M. (2007) Apoptosis, proliferation and differentiation patterns are influenced by Zebularine and SAHA in pancreatic cancer models. Scand. J. Gastroenterol., 42(1), 103-116.
80. Nawrocki, S.T.; Carew, J.S.; Pino, M.S.; Highshaw, R.A.; Andtbacka, R.H.; Dunner, K.Jr.; Pal, A.; Bornmann, W.G.; Chiao, P.J.; Huang, P.; Xiong, H.; Abbruzzese, J.L. and McConkey, D.J. (2006) Aggresome disruption: a novel strategy to enhance bortezomib-induced apoptosis in pancreatic cancer cells. Cancer Res., 66(7), 3773-3781.
81. Bai, J.; Demirjian, A.; Sui, J.; Marasco, W. and Callery, M.P. (2006) Histone deacetylase inhibitor trichostatin A and proteasome inhibitor PS-341 synergistically induce apoptosis in pancreatic cancer cells. Biochem. Biophys. Res. Commun., 348(4), 1245-1253.
82. Richards, D.A.; Boehm, K.A.; Waterhouse, D.M.; Wagener, D.J.; Krishnamurthi, S.S.; Rosemurgy, A.; Grove, W.; Macdonald, K.; Gulyas, S.; Clark, M. and Dasse, K.D. (2006) Gemcitabine plus CI-994 offers no advantage over gemcitabine alone in the treatment of patients with advanced pancreatic cancer: results of a phase II randomized, double-blind, placebo-controlled, multicenter study. Ann. Oncol., 17(7), 1096-1102.
83. Shin, S. and Verma, I.M. (2003) BRCA2 cooperates with histone acetyltransferases in androgen receptor-mediated transcription. Proc. Natl. Acad. Sci. USA, 100(12), 7201-7206.
84. Fuks, F.; Milner, J. and Kouzarides, T. (1998) BRCA2 associates with acetyltransferase activity when bound to P/CAF. Oncogene, 17(19), 2531-2534.
85. Siddique, H.; Zou, J.P.; Rao, V.N. and Reddy, E.S. (1998) The BRCA2 is a histone acetyltransferase. Oncogene, 16(17), 2283-2285.
86. Yarden, R.I. and Brody, L.C. (1999) BRCA1 interacts with components of the histone deacetylase complex. Proc. Natl. Acad. Sci. USA, 96(9), 4983-4988.
87. Bochar, D.A.; Wang, L.; Beniya, H.; Kinev, A.; Xue, Y.; Lane, W.S.; Wang, W.; Kashanchi, F. and Shiekhattar, R. (2000) BRCA1 is associated with a human SWI/SNF-related complex: linking chromatin remodeling to breast cancer. Cell, 102(2), 257-265.
88. Shi, Y.; Sawada, J.; Sui, G.; Affar el, B.; Whetstine, J.R.; Lan, F.; Ogawa, H.; Luke, M.P.; Nakatani, Y. and Shi, Y. (2003) Coordinated histone modifications mediated by a CtBP co-repressor complex. Nature, 422(6933), 735-738.
89. Subramanian, T. and Chinnadurai, G. (2003) Association of class I histone deacetylases with transcriptional corepressor CtBP. FEBS Lett., 540(1-3), 255-258.
90. Sundqvist, A.; Sollerbrant, K. and Svensson, C. (1998) The carboxy-terminal region of adenovirus E1A activates transcription through targeting of a C-terminal binding protein-histone deacetylase complex. FEBS Lett., 429(2), 183-188.
91. Zhang, Z.; Yamashita, H.; Toyama, T.; Yamamoto, Y.; Kawasoe, T. and Iwase, H. (2006) Reduced expression of the breast cancer metastasis suppressor 1 mRNA is correlated with poor progress in breast cancer. Clin. Cancer Res., 12(21), 6410-6414.
92. Hicks, D.G.; Yoder, B.J.; Short, S.; Tarr, S.; Prescott, N.; Crowe, J.P.; Dawson, A.E.; Budd, G.T.; Sizemore, S.; Cicek, M.; Choueiri, T.K.; Tubbs, R.R.; Gaile, D.; Nowak, N.; Accavitti-Loper, M.A.; Frost, A.R.; Welch, D.R. and Casey, G. (2006) Loss of breast cancer metastasis suppressor 1 protein expression predicts reduced disease-free survival in subsets of breast cancer patients. Clin. Cancer Res., 12(22), 6702-6708.
93. Lombardi, G.; Di Cristofano, C.; Capodanno, A.; Iorio, M.C.; Aretini, P.; Isola, P.; Tancredi, M.; Collecchi, P.; Naccarato, A.G.; Porta, R.P.; Bevilacqua, G. and Caligo, M.A. (2007) High level of messenger RNA for BRMS1 in primary breast carcinomas is associated with poor prognosis. Int. J. Cancer, 120(6), 1169-1178.
94. Mazumdar, A.; Wang, R.A.; Mishra, S.K.; Adam, L.; Bagheri-Yarmand, R.; Mandal, M.; Vadlamudi, R.K. and Kumar, R. (2001) Transcriptional repression of oestrogen receptor by metastasis-associated protein 1 corepressor. Nat. Cell Biol., 3(1), 30-37.
95. Lopez-Garcia, J.; Periyasamy, M.; Thomas, R.S.; Christian, M.; Leao, M.; Jat, P.; Kindle, K.B.; Heery, D.M.; Parker, M.G.; Buluwela, L.; Kamalati, T. and Ali, S. (2006) ZNF366 is an estrogen receptor corepressor that acts through CtBP and histone deacetylases. Nucleic Acids Res., 34(21), 6126-6136.
96. Green, K.A. and Carroll, J.S. (2007) Oestrogen-receptor-mediated transcription and the influence of co-factors and chromatin state. Nat. Rev. Cancer, 7(9), 713-722.
97. Krusche, C.A.; Wulfing, P.; Kersting, C.; Vloet, A.; Bocker, W.; Kiesel, L.; Beier, H.M. and Alfer, J. (2005) Histone deacetylase-1 and -3 protein expression in human breast cancer: a tissue microarray analysis. Breast Cancer Res. Treat., 90(1), 15-23.
98. Sambucetti, L.C.; Fischer, D.D.; Zabludoff, S.; Kwon, P.O.; Chamberlin, H.; Trogani, N.; Xu, H. and Cohen, D. (1999) Histone deacetylase inhibition selectively alters the activity and expression of cell cycle proteins leading to specific chromatin acetylation and antiproliferative effects. J. Biol.Chem., 274(49), 34940-34947.
99. Kim, M.S.; Son, M.W.; Kim, W.B.; In Park, Y. and Moon, A. (2000) Apicidin, an inhibitor of histone deacetylase, prevents H-ras-induced invasive phenotype. Cancer Lett., 157(1), 23-30.
100. Sandor, V.; Senderowicz, A.; Mertins, S.; Sackett, D.; Sausville, E.; Blagosklonny, M.V. and Bates, S.E. (2000) P21-dependent g(1)arrest with downregulation of cyclin D1 and upregulation of cyclin E by the histone deacetylase inhibitor FR901228. Br. J. Cancer, 83(6), 817-825.
101. Huang, L. and Pardee, A.B. (2000) Suberoylanilide hydroxamic acid as a potential therapeutic agent for human breast cancer treatment. Mol. Med., 6(10), 849-866.
102. Vigushin, D.M.; Ali, S.; Pace, P.E.; Mirsaidi, N.; Ito, K.; Adcock, I. and Coombes, R.C. (2001) Trichostatin A is a histone deacetylase inhibitor with potent antitumor activity against breast cancer in vivo. Clin. Cancer Res., 7(4), 971-976.
103. Louis, M.; Rosato, R.R.; Brault, L.; Osbild, S.; Battaglia, E.; Yang, X.H.; Grant, S. and Bagrel, D. (2004) The histone deacetylase inhibitor sodium butyrate induces breast cancer cell apoptosis through diverse cytotoxic actions including glutathione depletion and oxidative stress. Int. J. Oncol., 25(6), 1701-1711.
104. Lee, K.W.; Kim, J.H.; Park, J.H.; Kim, H.P.; Song, S.H.; Kim, S.G.; Kim, T.Y.; Jong, H.S.; Jung, K.H.; Im, S.A.; Kim, T.Y.; Kim, N.K. and Bang, Y.J. (2006) Antitumor activity of SK-7041, a novel histone deacetylase inhibitor, in human lung and breast cancer cells. Anticancer Res., 26(5A), 3429-3438.
105. Joung, K.E.; Min, K.N.; An, J.Y.; Kim, D.K.; Kong, G. and Sheen, Y.Y. (2006) Potent in vivo anti-breast cancer activity of IN-2001, a novel inhibitor of histone deacetylase, in MMTV/c-Neu mice. Cancer Res., 66(10), 5394-5402.
106. Pledgie-Tracy, A.; Sobolewski, M.D. and Davidson, N.E. (2007) Sulforaphane induces cell type-specific apoptosis in human breast cancer cell lines. Mol. Cancer Ther., 6(3), 1013-1021.
107. Arts, J.; Angibaud, P.; Marien, A.; Floren, W.; Janssens, B.; King, P.; van Dun, J.; Janssen, L.; Geerts, T.; Tuman, R.W.; Johnson, D.L.; Andries, L.; Jung, M.; Janicot, M. and van Emelen, K. (2007) R306465 is a novel potent inhibitor of class I histone deacetylases with broad-spectrum antitumoral activity against solid and haematological malignancies. Br. J. Cancer, 97(10), 1344-1353.
108. Im, J.Y.; Park, H.; Kang, K.W.; Choi, W.S. and Kim, H.S. (2008) Modulation of cell cycles and apoptosis by apicidin in estrogen receptor (ER)-positive and-negative human breast cancer cells. Chem. Biol. Interact., 172(3), 235-244.
109. Fortunati, N.; Bertino, S.; Costantino, L.; Bosco, O.; Vercellinatto, I.; Catalano, M.G. and Boccuzzi, G. (2008) Valproic acid is a selective antiproliferative agent in estrogen-sensitive breast cancer cells. Cancer Lett., 259(2), 156-164.
110. Park, H.; Im, J.Y.; Kim, J.; Choi, W.S. and Kim, H.S. (2008) Effects of apicidin, a histone deacetylase inhibitor, on the regulation of apoptosis in H-ras-transformed breast epithelial cells. Int. J. Mol. Med., 21(3), 325-333.
111. Yang, X.; Ferguson, A.T.; Nass, S.J.; Phillips, D.L.; Butash, K.A.; Wang, S.M.; Herman, J.G. and Davidson, N.E. (2000) Transcriptional activation of estrogen receptor alpha in human breast cancer cells by histone deacetylase inhibition. Cancer Res., 60(24), 6890-6894.
112. Munster, P.N.; Troso-Sandoval, T.; Rosen, N.; Rifkind, R.; Marks, P.A. and Richon, V.M. (2001) The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces differentiation of human breast cancer cells. Cancer Res., 61(23), 8492-8497.
113. Yang, X.; Phillips, D.L.; Ferguson, A.T.; Nelson, W.G.; Herman, J.G. and Davidson, N.E. (2001) Synergistic activation of functional estrogen receptor (ER)-alpha by DNA methyltransferase and histone deacetylase inhibition in human ER-alpha-negative breast cancer cells. Cancer Res., 61(19), 7025-7029.
114. Bovenzi, V. and Momparler, R.L. (2001) Antineoplastic action of 5-aza-2′-deoxycytidine and histone deacetylase inhibitor and their effect on the expression of retinoic acid receptor beta and estrogen receptor alpha genes in breast carcinoma cells. Cancer Chemother. Pharmacol., 48(1), 71-76.
115. Primeau, M.; Gagnon, J. and Momparler, R.L. (2003) Synergistic antineoplastic action of DNA methylation inhibitor 5-AZA-2′-deoxycytidine and histone deacetylase inhibitor depsipeptide on human breast carcinoma cells. Int. J. Cancer, 103(2), 177-184.
116. Gagnon, J.; Shaker, S.; Primeau, M.; Hurtubise, A. and Momparler, R.L. (2003) Interaction of 5-aza-2′-deoxycytidine and depsipeptide on antineoplastic activity and activation of 14-3-3sigma, E-cadherin and tissue inhibitor of metalloproteinase 3 expression in human breast carcinoma cells. Anticancer Drugs, 14(3), 193-202.
117. Keen, J.C.; Yan, L.; Mack, K.M.; Pettit, C.; Smith, D.; Sharma, D. and Davidson, N.E. (2003) A novel histone deacetylase inhibitor, scriptaid, enhances expression of functional estrogen receptor alpha (ER) in ER negative human breast cancer cells in combination with 5-aza 2′-deoxycytidine. Breast Cancer Res. Treat., 81(3), 177-186.
118. Hurtubise, A. and Momparler, R.L. (2006) Effect of histone deacetylase inhibitor LAQ824 on antineoplastic action of 5-Aza-2′-deoxycytidine (decitabine) on human breast carcinoma cells. Cancer Chemother. Pharmacol., 58(5), 618-625.
119. Chavez-Blanco, A.; Perez-Plasencia, C.; Perez-Cardenas, E.; Carrasco-Legleu, C.; Rangel-Lopez, E.; Segura-Pacheco, B.; Taja-Chayeb, L.; Trejo-Becerril, C.; Gonzalez-Fierro, A.; Candelaria, M.; Cabrera, G. and Duenas-Gonzalez, A. (2006) Antineoplastic effects of the DNA methylation inhibitor hydralazine and the histone deacetylase inhibitor valproic acid in cancer cell lines. Cancer Cell Int., 6, 2.
120. Fan, J.; Yin, W.J.; Lu, J.S.; Wang, L.; Wu, J.; Wu, F.Y.; Di, G.H.; Shen, Z.Z. and Shao, Z.M. (2008) ER alpha negative breast cancer cells restore response to endocrine therapy by combination treatment with both HDAC inhibitor and DNMT inhibitor. J. Cancer Res. Clin. Oncol., 134(8), 883-890.
121. Jang, E.R.; Lim, S.J.; Lee, E.S.; Jeong, G.; Kim, T.Y.; Bang, Y.J. and Lee, J.S. (2004) The histone deacetylase inhibitor trichostatin A sensitizes estrogen receptor alpha-negative breast cancer cells to tamoxifen. Oncogene, 23(9), 1724-1736.
122. Fuino, L.; Bali, P.; Wittmann, S.; Donapaty, S.; Guo, F.; Yamaguchi, H.; Wang, H.G.; Atadja, P. and Bhalla, K. (2003) Histone deacetylase inhibitor LAQ824 down-regulates Her-2 and sensitizes human breast cancer cells to trastuzumab, taxotere, gemcitabine, and epothilone B. Mol. Cancer Ther., 2(10), 971-984.
123. Bali, P.; Pranpat, M.; Swaby, R.; Fiskus, W.; Yamaguchi, H.; Balasis, M.; Rocha, K.; Wang, H.G.; Richon, V. and Bhalla, K. (2005) Activity of suberoylanilide hydroxamic Acid against human breast cancer cells with amplification of her-2. Clin. Cancer Res., 11(17), 6382-6389.
124. Louis, M.; Rosato, R.R.; Battaglia, E.; Neguesque, A.; Lapotre, A.; Grant, S. and Bagrel, D. (2005) Modulation of sensitivity to doxorubicin by the histone deacetylase inhibitor sodium butyrate in breast cancer cells. Int. J. Oncol., 26(6), 1569-1574.
125. Qian, D.Z.; Wang, X.; Kachhap, S.K.; Kato, Y.; Wei, Y.; Zhang, L.; Atadja, P. and Pili, R. (2004) The histone deacetylase inhibitor NVP-LAQ824 inhibits angiogenesis and has a greater antitumor effect in combination with the vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ZK222584. Cancer Res., 64(18), 6626-6634.
126. Mitchell, C.; Park, M.A.; Zhang, G.; Yacoub, A.; Curiel, D.T.; Fisher, P.B.; Roberts, J.D.; Grant, S. and Dent, P. (2007) Extrinsic pathway- and cathepsin-dependent induction of mitochondrial dysfunction are essential for synergistic flavopiridol and vorinostat lethality in breast cancer cells. Mol. Cancer Ther., 6(12 Pt1), 3101-3112.
127. Chopin, V.; Slomianny, C.; Hondermarck, H. and Le Bourhis, X. (2004) Synergistic induction of apoptosis in breast cancer cells by cotreatment with butyrate and TNF-alpha, TRAIL, or anti-Fas agonist antibody involves enhancement of death receptors' signaling and requires P21(waf1). Exp. Cell Res., 298(2), 560-573.
128. Butler, L.M.; Liapis, V.; Bouralexis, S.; Welldon, K.; Hay, S.; Thai le, M.; Labrinidis, A.; Tilley, W.D.; Findlay, D.M. and Evdokiou, A. (2006) The histone deacetylase inhibitor, suberoylanilide hydroxamic acid, overcomes resistance of human breast cancer cells to Apo2L/TRAIL. Int. J. Cancer, 119(4), 944-954.
129. Kuljaca, S.; Liu, T.; Tee, A.E.; Haber, M.; Norris, M.D.; Dwarte, T. and Marshall, G.M. (2007) Enhancing the anti-angiogenic action of histone deacetylase inhibitors. Mol. Cancer, 6, 68.
130. Domingo-Domenech, J.; Pippa, R.; Tapia, M.; Gascon, P.; Bachs, O. and Bosch, M. (2007) Inactivation of NF-kappaB by proteasome inhibition contributes to increased apoptosis induced by histone deacetylase inhibitors in human breast cancer cells. Breast Cancer Res. Treat., 112(1), 53-62.
131. Gray, S.G. and De Meyts, P. (2005) Role of histone and transcription factor acetylation in diabetes pathogenesis. Diabetes Metab. Res. Rev., 21(5), 416-433.
132. Batta, K.; Das, C.; Gadad, S.; Shandilya, J. and Kundu, T.K. (2007) Reversible acetylation of non histone proteins: role in cellular function and disease. Subcell. Biochem., 41, 193-212.
133. Yamauchi, T.; Oike, Y.; Kamon, J.; Waki, H.; Komeda, K.; Tsuchida, A.; Date, Y.; Li, M.X.; Miki, H.; Akanuma, Y.; Nagai, R.; Kimura, S.; Saheki, T.; Nakazato, M.; Naitoh, T.; Yamamura, K. and Kadowaki, T. (2002) Increased insulin sensitivity despite lipodystrophy in Crebbp heterozygous mice. Nat. Genet., 30(2), 221-226.
134. James, S. and Kaiser, C. Methods for identification of compounds modulating insulin resistance, in: B. AB (Ed.), BIOVITRUM AB (SE), 2003. Patent EP20030762946 http://www.freepatentsonline.com/EP1539217A2.html
135. Kim, H.B.; Kong, M.; Kim, T.M.; Suh, Y.H.; Kim, W.H.; Lim, J.H.; Song, J.H. and Jung, M.H. (2006) NFATc4 and ATF3 negatively regulate adiponectin gene expression in 3T3-L1 adipocytes. Diabetes, 55(5), 1342-1352.
136. Qiao, L.; Schaack, J. and Shao, J. (2006) Suppression of adiponectin gene expression by histone deacetylase inhibitor valproic acid. Endocrinology, 147(2), 865-874.
137. Qiang, L.; Wang, H. and Farmer, S.R. (2007) Adiponectin secretion is regulated by SIRT1 and the endoplasmic reticulum oxidoreductase Ero1-L{alpha}. Mol. Cell. Biol., 27(13), 4698-4707.
138. Lee, J.H.; Kim, K.A.; Kwon, K.B.; Kim, E.K.; Lee, Y.R.; Song, M.Y.; Koo, J.H.; Ka, S.O.; Park, J.W. and Park, B.H. (2007) Diallyl disulfide accelerates adipogenesis in 3T3-L1 cells. Int. J. Mol. Med., 20(1), 59-64.
139. Wiper-Bergeron, N.; Wu, D.; Pope, L.; Schild-Poulter, C. and Hache, R.J. (2003) Stimulation of preadipocyte differentiation by steroid through targeting of an HDAC1 complex. EMBO J., 22(9), 2135-2145.
140. Zuo, Y.; Qiang, L. and Farmer, S.R. (2006) Activation of CCAAT/ enhancer-binding protein (C/EBP) alpha expression by C/EBP beta during adipogenesis requires a peroxisome proliferator-activated receptor-gamma-associated repression of HDAC1 at the C/ebp alpha gene promoter. J. Biol.Chem., 281(12), 7960-7967.
141. Brown, R.; Imran, S.A.; Ur, E. and Wilkinson, M. (2008) Valproic Acid and CEBPalpha-Mediated Regulation of Adipokine Gene Expression in Hypothalamic Neurons and 3T3-L1 Adipocytes. Neuroendocrinology, 88(1), 25-34.
142. Wiper-Bergeron, N.; Salem, H.A.; Tomlinson, J.J.; Wu, D. and Hache, R.J. (2007) Glucocorticoid-stimulated preadipocyte differentiation is mediated through acetylation of C/EBPbeta by GCN5. Proc. Natl. Acad. Sci. USA, 104(8), 2703-2708.
143. Fu, M.; Rao, M.; Bouras, T.; Wang, C.; Wu, K.; Zhang, X.; Li, Z.; Yao, T.P. and Pestell, R.G. (2005) Cyclin D1 inhibits peroxisome proliferator-activated receptor gamma-mediated adipogenesis through histone deacetylase recruitment. J. Biol.Chem., 280(17), 16934-16941.
144. Yoo, E.J.; Chung, J.J.; Choe, S.S.; Kim, K.H. and Kim, J.B. (2006) Down-regulation of histone deacetylases stimulates adipocyte differentiation. J. Biol.Chem., 281(10), 6608-6615.
145. Jin, C.; Kato, K.; Chimura, T.; Yamasaki, T.; Nakade, K.; Murata, T.; Li, H.; Pan, J.; Zhao, M.; Sun, K.; Chiu, R.; Ito, T.; Nagata, K.; Horikoshi, M. and Yokoyama, K.K. (2006) Regulation of histone acetylation and nucleosome assembly by transcription factor JDP2. Nat. Struct. Mol. Biol., 13(4), 331-338.
146. Pan, J.; Jin, C.; Murata, T. and Yokoyama, K.K. (2003) Sequence specific transcription factor, JDP2 interacts with histone and inhibits p300-mediated histone acetylation. Nucleic Acids Res. Suppl., (3), 305-306.
147. Pan, J.; Jin, C.; Murata, T. and Yokoyama, K.K. (2004) Sequence specific transcription factor, JDP2 interacts with histone and inhibits p300-mediated histone acetylation. Nucleic Acids Symp. Ser. (Oxf), (48), 189-190.
148. Nakade, K.; Pan, J.; Yoshiki, A.; Ugai, H.; Kimura, M.; Liu, B.; Li, H.; Obata, Y.; Iwama, M.; Itohara, S.; Murata, T. and Yokoyama, K.K. (2007) JDP2 suppresses adipocyte differentiation by regulating histone acetylation. Cell Death Differ., 14(8), 1398-1405.
149. Guan, H.P.; Ishizuka, T.; Chui, P.C.; Lehrke, M. and Lazar, M.A. (2005) Corepressors selectively control the transcriptional activity of PPARgamma in adipocytes. Genes Dev., 19(4), 453-461.
150. Hartman, H.B.; Hu, X.; Tyler, K.X.; Dalal, C.K. and Lazar, M.A. (2002) Mechanisms regulating adipocyte expression of resistin. J. Biol. Chem., 277(22), 19754-19761.
151. Bai, L.; Pang, W.J.; Yang, Y.J. and Yang, G.S. (2008) Modulation of Sirt1 by resveratrol and nicotinamide alters proliferation and differentiation of pig preadipocytes. Mol. Cell. Biochem., 307(1-2), 129-140.
152. Shi, T.; Wang, F.; Stieren, E. and Tong, Q. (2005) SIRT3, a mitochondrial sirtuin deacetylase, regulates mitochondrial function and thermogenesis in brown adipocytes. J. Biol.Chem., 280(14), 13560-13567.
153. Lee, Y.S.; Lee, H.H.; Park, J.; Yoo, E.J.; Glackin, C.A.; Choi, Y.I.; Jeon, S.H.; Seong, R.H.; Park, S.D. and Kim, J.B. (2003) Twist2, a novel ADD1/SREBP1c interacting protein, represses the transcriptional activity of ADD1/SREBP1c. Nucleic Acids Res., 31(24), 7165-7174.
154. Giandomenico, V.; Simonsson, M.; Gronroos, E. and Ericsson, J. (2003) Coactivator-dependent acetylation stabilizes members of the SREBP family of transcription factors. Mol. Cell. Biol., 23(7), 2587-2599.
155. Wagner, B.L.; Valledor, A.F.; Shao, G.; Daige, C.L.; Bischoff, E.D.; Petrowski, M.; Jepsen, K.; Baek, S.H.; Heyman, R.A.; Rosenfeld, M.G.; Schulman, I.G. and Glass, C.K. (2003) Promoter-specific roles for liver X receptor/corepressor complexes in the regulation of ABCA1 and SREBP1 gene expression. Mol. Cell. Biol., 23(16), 5780-5789.
156. Jakkaraju, S.; Zhe, X.; Pan, D.; Choudhury, R. and Schuger, L. (2005) TIPs are tension-responsive proteins involved in myogenic versus adipogenic differentiation. Dev. Cell, 9(1), 39-49.
157. Gupta, P.; Park, S.W.; Farooqui, M. and Wei, L.N. (2007) Orphan nuclear receptor TR2, a mediator of preadipocyte proliferation, is differentially regulated by RA through exchange of coactivator PCAF with corepressor RIP140 on a platform molecule GRIP1. Nucleic Acids Res., 35(7), 2269-2282.
158. Evans-Molina, C.; Garmey, J.C.; Ketchum, R.; Brayman, K.L.; Deng, S. and Mirmira, R.G. (2007) Glucose regulation of insulin gene transcription and pre-mRNA processing in human islets. Diabetes, 56(3), 827-835.
159. Lee, J.H.; Volinic, J.L.; Banz, C.; Yao, K.M. and Thomas, M.K. (2005) Interactions with p300 enhance transcriptional activation by the PDZ-domain coactivator Bridge-1. J. Endocrinol., 187(2), 283-292.
160. Wang, H.W.; Muguira, M.; Liu, W.D.; Zhang, T.; Chen, C.; Aucoin, R.; Breslin, M. and Lan, M. (2008) Identification of an INSM1 binding site in the insulin promoter: Negative regulation of the insulin gene transcription. J. Endocrinol., 198, 29-39
161. Karnik, S.K.; Chen, H.; McLean, G.W.; Heit, J.J.; Gu, X.; Zhang, A.Y.; Fontaine, M.; Yen, M.H. and Kim, S.K. (2007) Menin controls growth of pancreatic beta-cells in pregnant mice and promotes gestational diabetes mellitus. Science, 318(5851), 806-809.
162. Kim, H.; Lee, J.E.; Cho, E.J.; Liu, J.O. and Youn, H.D. (2003) Menin, a tumor suppressor, represses JunD-mediated transcriptional activity by association with an mSin3A-histone deacetylase complex. Cancer Res., 63(19), 6135-6139.
163. Gobl, A.E.; Berg, M.; Lopez-Egido, J.R.; Oberg, K.; Skogseid, B. and Westin, G. (1999) Menin represses JunD-activated transcription by a histone deacetylase-dependent mechanism. Biochim. Biophys. Acta, 1447(1), 51-56.
164. Malecki, M.T.; Jhala, U.S.; Antonellis, A.; Fields, L.; Doria, A.; Orban, T.; Saad, M.; Warram, J.H.; Montminy, M. and Krolewski, A.S. (1999) Mutations in NEUROD1 are associated with the development of type 2 diabetes mellitus. Nat. Genet., 23(3), 323-328.
165. Sharma, A.; Moore, M.; Marcora, E.; Lee, J.E.; Qiu, Y.; Samaras, S. and Stein, R. (1999) The NeuroD1/BETA2 sequences essential for insulin gene transcription colocalize with those necessary for neurogenesis and p300/ CREB binding protein binding. Mol. Cell. Biol., 19(1), 704-713.
166. Qiu, Y.; Guo, M.; Huang, S. and Stein, R. (2002) Insulin gene transcription is mediated by interactions between the p300 coactivator and PDX-1, BETA2, and E47. Mol. Cell. Biol., 22(2), 412-420.
167. Qiu, Y.; Sharma, A. and Stein, R. (1998) p300 mediates transcriptional stimulation by the basic helix-loop-helix activators of the insulin gene. Mol. Cell. Biol., 18(5), 2957-2964.
168. Qiu, Y.; Guo, M.; Huang, S. and Stein, R. (2004) Acetylation of the BETA2 Transcription Factor by p300-associated Factor Is Important in Insulin Gene Expression. J. Biol. Chem., 279(11), 9796-9802.
169. Liu, W.D.; Wang, H.W.; Muguira, M.; Breslin, M.B. and Lan, M.S. (2006) INSM1 functions as a transcriptional repressor of the neuroD/beta2 gene through the recruitment of cyclin D1 and histone deacetylases. Biochem. J., 397(1), 169-177.
170. Breslin, M.B.; Wang, H.W.; Pierce, A.; Aucoin, R. and Lan, M.S. (2007) Neurogenin 3 recruits CBP co-activator to facilitate histone H3/H4 acetylation in the target gene INSM1. FEBS Lett., 581(5), 949-954.
171. Kemp, D.M.; Lin, J.C. and Habener, J.F. (2003) Regulation of Pax4 paired homeodomain gene by neuron-restrictive silencer factor. J. Biol.Chem., 278(37), 35057-35062.
172. Grzeskowiak, R.; Amin, J.; Oetjen, E. and Knepel, W. (2000) Insulin responsiveness of the glucagon gene conferred by interactions between proximal promoter and more distal enhancer-like elements involving the paired-domain transcription factor Pax6. J. Biol. Chem., 275(39), 30037-30045.
173. Chakrabarti, S.K.; James, J.C. and Mirmira, R.G. (2002) Quantitative assessment of gene targeting in vitro and in vivo by the pancreatic transcription factor, Pdx1. Importance of chromatin structure in directing promoter binding. J. Biol. Chem., 277(15), 13286-13293.
174. Gerrish, K.; Van Velkinburgh, J.C. and Stein, R. (2004) Conserved transcriptional regulatory domains of the pdx-1 gene. Mol. Endocrinol., 18(3), 533-548.
175. Stanojevic, V.; Habener, J.F. and Thomas, M.K. (2004) Pancreas duodenum homeobox-1 transcriptional activation requires interactions with p300. Endocrinology, 145(6), 2918-2928.
176. Mosley, A.L. and Ozcan, S. (2004) The pancreatic duodenal homeobox-1 protein (Pdx-1) interacts with histone deacetylases Hdac-1 and Hdac-2 on low levels of glucose. J. Biol. Chem., 279(52), 54241-54247.
177. Mosley, A.L.; Corbett, J.A. and Ozcan, S. (2004) Glucose regulation of insulin gene expression requires the recruitment of p300 by the beta-cell-specific transcription factor Pdx-1. Mol. Endocrinol., 18(9), 2279-2290.
178. Wang, H.W.; Breslin, M.B. and Lan, M.S. (2007) Pdx-1 modulates histone H4 acetylation and insulin gene expression in terminally differentiated alpha-TC-1 cells. Pancreas, 34(2), 248-253.
179. Iguchi, H.; Ikeda, Y.; Okamura, M.; Tanaka, T.; Urashima, Y.; Ohguchi, H.; Takayasu, S.; Kojima, N.; Iwasaki, S.; Ohashi, R.; Jiang, S.; Hasegawa, G.; Ioka, R.X.; Magoori, K.; Sumi, K.; Maejima, T.; Uchida, A.; Naito, M.; Osborne, T.F.; Yanagisawa, M.; Yamamoto, T.T.; Kodama, T. and Sakai, J. (2005) SOX6 attenuates glucose-stimulated insulin secretion by repressing PDX1 transcriptional activity and is down-regulated in hyperinsulinemic obese mice. J. Biol. Chem., 280(45), 37669-37680.
180. Iguchi, H.; Urashima, Y.; Inagaki, Y.; Ikeda, Y.; Okamura, M.; Tanaka, T.; Uchida, A.; Yamamoto, T.T.; Kodama, T. and Sakai, J. (2007) SOX6 suppresses cyclin D1 promoter activity by interacting with beta-catenin and histone deacetylase 1, and its downregulation induces pancreatic beta-cell proliferation. J. Biol. Chem., 282(26), 19052-19061.
181. Furumatsu, T.; Tsuda, M.; Yoshida, K.; Taniguchi, N.; Ito, T.; Hashimoto, M.; Ito, T. and Asahara, H. (2005) Sox9 and p300 cooperatively regulate chromatin-mediated transcription. J. Biol. Chem., 280(42), 35203-35208.
182. Lynn, F.C.; Smith, S.B.; Wilson, M.E.; Yang, K.Y.; Nekrep, N. and German, M.S. (2007) Sox9 coordinates a transcriptional network in pancreatic progenitor cells. Proc. Natl. Acad. Sci. USA, 104(25), 10500-10505.
183. Seymour, P.A.; Freude, K.K.; Tran, M.N.; Mayes, E.E.; Jensen, J.; Kist, R.; Scherer, G. and Sander, M. (2007) SOX9 is required for maintenance of the pancreatic progenitor cell pool. Proc. Natl. Acad. Sci. USA, 104(6), 1865-1870.
184. Korsgren, O.; Andersson, A. and Sandler, S. (1993) Pretreatment of fetal porcine pancreas in culture with nicotinamide accelerates reversal of diabetes after transplantation to nude mice. Surgery, 113(2), 205-214.
185. Sandler, S.; Andersson, A.; Korsgren, O.; Tollemar, J.; Petersson, B.; Groth, C.G. and Hellerstrom, C. (1989) Tissue culture of human fetal pancreas. Effects of nicotinamide on insulin production and formation of isletlike cell clusters. Diabetes, 38(Suppl 1), 168-171.
186. Schein, P.S.; Cooney, D.A. and Vernon, M.L. (1967) The use of nicotinamide to modify the toxicity of streptozotocin diabetes without loss of antitumor activity. Cancer Res., 27(12), 2324-2332.
187. Stauffacher, W.; Burr, I.; Gutzeit, A.; Beaven, D.; Veleminsky, J. and Renold, A.E. (1970) Streptozotocin diabetes: time course of irreversible B-cell damage; further observations on prevention by nicotinamide. Proc. Soc. Exp. Biol. Med., 133(1), 194-200.
188. Gale, E.A.; Bingley, P.J.; Emmett, C.L. and Collier, T. (2004) European Nicotinamide Diabetes Intervention Trial (ENDIT): a randomised controlled trial of intervention before the onset of type 1 diabetes. Lancet, 363(9413), 925-931.
189. Hedman, M.; Ludvigsson, J. and Faresjo, M.K. (2006) Nicotinamide reduces high secretion of IFN-gamma in high-risk relatives even though it does not prevent type 1 diabetes. J. Interferon Cytokine Res., 26(4), 207-213.
190. Liu, H.K.; Green, B.D.; Flatt, P.R.; McClenaghan, N.H. and McCluskey, J.T. (2004) Effects of long-term exposure to nicotinamide and sodium butyrate on growth, viability, and the function of clonal insulin secreting cells. Endocr. Res., 30(1), 61-68.
191. Larsen, L.; Tonnesen, M.; Ronn, S.G.; Storling, J.; Jorgensen, S.; Mascagni, P.; Dinarello, C.A.; Billestrup, N. and Mandrup-Poulsen, T. (2007) Inhibition of histone deacetylases prevents cytokine-induced toxicity in beta cells. Diabetologia, 50(4), 779-789.
192. Tveten, K.; Holla, O.L.; Ranheim, T.; Berge, K.E.; Leren, T.P. and Kulseth, M.A. (2007) 4-Phenylbutyrate restores the functionality of a misfolded mutant low-density lipoprotein receptor. Febs J., 274(8), 1881-1893.
193. Gangaram-Panday, S.T.; Faas, M.M. and de Vos, P. (2007) Towards stem-cell therapy in the endocrine pancreas. Trends Mol. Med., 13(4), 164-173.
194. Lee, J.H.; Hart, S.R. and Skalnik, D.G. (2004) Histone deacetylase activity is required for embryonic stem cell differentiation. Genesis, 38(1), 32-38.
195. Okazaki, K. and Maltepe, E. (2006) Oxygen, epigenetics and stem cell fate. Regen. Med., 1(1), 71-83.
196. Romagnani, P.; Lasagni, L.; Mazzinghi, B.; Lazzeri, E. and Romagnani, S. (2007) Pharmacological modulation of stem cell function. Curr. Med. Chem., 14(10), 1129-1139.
197. Lumelsky, N.; Blondel, O.; Laeng, P.; Velasco, I.; Ravin, R. and McKay, R. (2001) Differentiation of embryonic stem cells to insulin-secreting structures similar to pancreatic islets. Science, 292(5520), 1389-1394.
198. Tayaramma, T.; Ma, B.; Rohde, M. and Mayer, H. (2006) Chromatin-remodeling factors allow differentiation of bone marrow cells into insulin-producing cells. Stem Cells, 24(12), 2858-2867.
199. Sun, Y.; Chen, L.; Hou, X.G.; Hou, W.K.; Dong, J.J.; Sun, L.; Tang, K.X.; Wang, B.; Song, J.; Li, H. and Wang, K.X. (2007) Differentiation of bone marrow-derived mesenchymal stem cells from diabetic patients into insulin-producing cells in vitro. Chin. Med. J. (Engl), 120(9), 771-776.
200. Goicoa, S.; Alvarez, S.; Ricordi, C.; Inverardi, L. and Dominguez-Bendala, J. (2006) Sodium butyrate activates genes of early pancreatic development in embryonic stem cells. Cloning Stem Cells, 8(3), 140-149.
201. Jiang, J.; Au, M.; Lu, K.; Eshpeter, A.; Korbutt, G.; Fisk, G. and Majumdar, A.S. (2007) Generation of insulin-producing islet-like clusters from human embryonic stem cells. Stem Cells, 25(8), 1940-1953.
202. Ramanujam, M. and Davidson, A. (2008) Targeting of the immune system in systemic lupus erythematosus. Expert. Rev. Mol. Med., 10, e2.
203. Rahman, A. and Isenberg, D.A. (2008) N. Engl. J. Med., 358(9), 929-939.
204. Gray, S.G. and Dangond, F. (2006) Rationale for the use of histone deacetylase inhibitors as a dual therapeutic modality in multiple sclerosis. Epigenetics, 1(2), 67-75.
205. Garcia, B.A.; Busby, S.A.; Shabanowitz, J.; Hunt, D.F. and Mishra, N. (2005) Resetting the epigenetic histone code in the MRL-lpr/lpr mouse model of lupus by histone deacetylase inhibition. J. Proteome Res., 4(6), 2032-2042.
206. Lu, X.; Kovalev, G.; Chang, H.; Kallin, E.; Knudsen, G.; Li, X.; Mishra, N.; Ruiz, P.; Li, E.; Su, L. and Zhang, Y. (2008) Inactivation of nurd component MTA2 causes abnormal T cell activation and lupus-like disease in mice. J. Biol. Chem., 283(20), 13825-13833.
207. Kaneko, T.; Hosokawa, H.; Yamashita, M.; Wang, C.R.; Hasegawa, A.; Kimura, M.Y.; Kitajiama, M.; Kimura, F.; Miyazaki, M. and Nakayama, T. (2007) Chromatin remodeling at the Th2 cytokine gene loci in human type 2 helper T cells. Mol. Immunol., 44(9), 2249-2256.
208. Mishra, N.; Brown, D.R.; Olorenshaw, I.M. and Kammer, G.M. (2001) Reverses skewed expression of CD154, interleukin-10, and interferon-gamma gene and protein expression in lupus T cells. Proc. Natl. Acad. Sci. USA, 98(5), 2628-2633.
209. Mishra, N.; Reilly, C.M.; Brown, D.R.; Ruiz, P. and Gilkeson, G.S. (2003) Histone deacetylase inhibitors modulate renal disease in the MRL-lpr/lpr mouse. J. Clin. Invest., 111(4), 539-552.
210. Lu, Z.P.; Ju, Z.L.; Shi, G.Y.; Zhang, J.W. and Sun, J. (2005) Histone deacetylase inhibitor Trichostatin A reduces anti-DNA autoantibody production and represses IgH gene transcription. Biochem. Biophys. Res. Commun., 330(1), 204-209.
211. Reilly, C.M.; Mishra, N.; Miller, J.M.; Joshi, D.; Ruiz, P.; Richon, V.M.; Marks, P.A. and Gilkeson, G.S. (2004) Modulation of renal disease in MRL/lpr mice by suberoylanilide hydroxamic acid. J. Immunol., 173(6), 4171-4178.
212. Li, N.; Zhao, D.; Kirschbaum, M.; Zhang, C.; Lin, C.L.; Todorov, I.; Kandeel, F.; Forman, S. and Zeng, D. (2008) HDAC inhibitor reduces cytokine storm and facilitates induction of chimerism that reverses lupus in anti-CD3 conditioning regimen. Proc. Natl. Acad. Sci. USA, 105(12), 4796-4801.
213. Su, R.C.; Becker, A.B.; Kozyrskyj, A.L. and Hayglass, K.T. (2008) Epigenetic regulation of established human type 1 versus type 2 cytokine responses. J. Allergy Clin. Immunol., 121(1), 57-63. e53.
214. Abbas, A.K.; Murphy, K.M. and Sher, A. (1996) Functional diversity of helper T lymphocytes. Nature, 383(6603), 787-793.
215. O'Garra, A. (1998) Cytokines induce the development of functionally heterogeneous T helper cell subsets. Immunity, 8(3), 275-283.
216. Chitnis, T. (2007) The role of CD4 T cells in the pathogenesis of multiple sclerosis. Int. Rev. Neurobiol., 79, 43-72.
217. Morinobu, A.; Kanno, Y. and O'Shea, J.J. (2004) Discrete roles for histone acetylation in human T helper 1 cell-specific gene expression. J. Biol. Chem., 279(39), 40640-40646.
218. Brogdon, J.L.; Xu, Y.; Szabo, S.J.; An, S.; Buxton, F.; Cohen, D. and Huang, Q. (2007) Histone deacetylase activities are required for innate immune cell control of Th1 but not Th2 effector cell function. Blood, 109(3), 1123-1130.
219. Kuchroo, V.K.; Das, M.P.; Brown, J.A.; Ranger, A.M.; Zamvil, S.S.; Sobel, R.A.; Weiner, H.L.; Nabavi, N. and Glimcher, L.H. (1995) B7-1 and B7-2 costimulatory molecules activate differentially the Th1/Th2 developmental pathways: application to autoimmune disease therapy. Cell, 80(5), 707-718.
220. Leonard, J.P.; Waldburger, K.E. and Goldman, S.J. (1995) Prevention of experimental autoimmune encephalomyelitis by antibodies against interleukin 12. J. Exp. Med., 181(1), 381-386.
221. Bright, J.J.; Musuro, B.F.; Du, C. and Sriram, S. (1998) Expression of IL-12 in CNS and lymphoid organs of mice with experimental allergic encephalitis. J. Neuroimmunol., 82(1), 22-30.
222. Lu, J.; Sun, H.; Wang, X.; Liu, C.; Xu, X.; Li, F. and Huang, B. (2005) Interleukin-12 p40 promoter activity is regulated by the reversible acetylation mediated by HDAC1 and p300. Cytokine, 31(1), 46-51.
223. Dangond, F.; Hafler, D.A.; Tong, J.K.; Randall, J.; Kojima, R.; Utku, N. and Gullans, S.R. (1998) Differential display cloning of a novel human histone deacetylase (HDAC3) cDNA from PHA-activated immune cells Biochem. Biophys. Res. Commun., 242(3), 648-652.
224. Dangond, F. and Gullans, S.R. (1998) Differential expression of human histone deacetylase mRNAs in response to immune cell apoptosis induction by trichostatin A and butyrate. Biochem. Biophys. Res. Commun., 247(3), 833-837.
225. Saemann, M.D.; Bohmig, G.A.; Osterreicher, C.H.; Burtscher, H.; Parolini, O.; Diakos, C.; Stockl, J.; Horl, W.H. and Zlabinger, G.J. (2000) Anti-inflammatory effects of sodium butyrate on human monocytes: potent inhibition of IL-12 and up-regulation of IL-10 production. Faseb J., 14(15), 2380-2382.
226. Ghosh, S.; May, M.J. and Kopp, E.B. (1998) NF-kappa B and Rel proteins: evolutionarily conserved mediators of immune responses. Annu. Rev. Immunol., 16(1), 225-260.
227. Baldwin, A.S.Jr. (1996) The NF-kappa B and I kappa B proteins: new discoveries and insights. Annu. Rev. Immunol., 14(1), 649-683.
228. Luhrs, H.; Gerke, T.; Boxberger, F.; Backhaus, K.; Melcher, R.; Scheppach, W. and Menzel, T. (2001) Butyrate inhibits interleukin-1-mediated nuclear factor-kappa B activation in human epithelial cells. Dig. Dis. Sci., 46(9), 1968-1973.
229. Luhrs, H.; Gerke, T.; Schauber, J.; Dusel, G.; Melcher, R.; Scheppach, W. and Menzel, T. (2001) Cytokine-activated degradation of inhibitory kappaB protein alpha is inhibited by the short-chain fatty acid butyrate. Int. J. Colorectal Dis., 16(4), 195-201.
230. Andoh, A.; Fujiyama, Y.; Shimada, M. and Bamba, T. (2000) Modulation of complement component (C3 and factor B) biosynthesis by a histone deacetylase inhibitor in human intestinal epithelial cells. Int. J. Mol. Med., 6(1), 51-54.
231. Andoh, A.; Fujiyama, Y.; Hata, K.; Araki, Y.; Takaya, H.; Shimada, M. and Bamba, T. (1999) Counter-regulatory effect of sodium butyrate on tumour necrosis factor- alpha (TNF-alpha)-induced complement C3 and factor B biosynthesis in human intestinal epithelial cells. Clin. Exp. Immunol., 118(1), 23-29.
232. Gibson, P.R.; Rosella, O.; Wilson, A.J.; Mariadason, J.M.; Rickard, K.; Byron, K. and Barkla, D.H. (1999) Colonic epithelial cell activation and the paradoxical effects of butyrate. Carcinogenesis, 20(4), 539-544.
233. Segain, J.P.; Raingeard de la Bletiere, D.; Bourreille, A.; Leray, V.; Gervois, N.; Rosales, C.; Ferrier, L.; Bonnet, C.; Blottiere, H.M. and Galmiche, J.P. (2000) Butyrate inhibits inflammatory responses through NFkappaB inhibition: implications for Crohn's disease. Gut, 47(3), 397-403.
234. Martin-Saavedra, F.M.; Flores, N.; Dorado, B.; Eguiluz, C.; Bravo, B.; Garcia-Merino, A. and Ballester, S. (2007) Beta-interferon unbalances the peripheral T cell proinflammatory response in experimental autoimmune encephalomyelitis. Mol. Immunol., 44(14), 3597-3607.
235. O'Connor, K.C.; Bar-Or, A. and Hafler, D.A. (2001) The neuroimmunology of multiple sclerosis: possible roles of T and B lymphocytes in immunopathogenesis. J. Clin. Immunol., 21(2), 81-92.
236. Takahashi, I.; Miyaji, H.; Yoshida, T.; Sato, S. and Mizukami, T. (1996) Selective inhibition of IL-2 gene expression by trichostatin A, a potent inhibitor of mammalian histone deacetylase. J. Antibiotics, 49(5), 453-457.
237. Matsuoka, H.; Fujimura, T.; Mori, H.; Aramori, I. and Mutoh, S. (2007) Mechanism of HDAC inhibitor FR235222-mediated IL-2 transcriptional repression in Jurkat cells. Int. Immunopharmacol., 7(11), 1422-1432.
238. Koyama, Y.; Adachi, M.; Sekiya, M.; Takekawa, M. and Imai, K. (2000) Histone deacetylase inhibitors suppress IL-2-mediated gene expression prior to induction of apoptosis. Blood, 96(4), 1490-1495.
239. Matsuoka, H.; Fujimura, T.; Hayashi, M.; Matsuda, K.; Ishii, Y.; Aramori, I. and Mutoh, S. (2007) Disruption of HDAC4/N-CoR complex by histone deacetylase inhibitors leads to inhibition of IL-2 gene expression. Biochem. Pharmacol., 74(3), 465-476.
240. Tao, R.; de Zoeten, E.F.; Ozkaynak, E.; Chen, C.; Wang, L.; Porrett, P.M.; Li, B.; Turka, L.A.; Olson, E.N.; Greene, M.I.; Wells, A.D. and Hancock, W.W. (2007) Deacetylase inhibition promotes the generation and function of regulatory T cells. Nat. Med., 13(11), 1299-1307.
241. Camelo, S.; Iglesias, A.H.; Hwang, D.; Due, B.; Ryu, H.; Smith, K.; Gray, S.G.; Imitola, J.; Duran, G.; Assaf, B.; Langley, B.; Khoury, S.J.; Stephanopoulos, G.; De Girolami, U.; Ratan, R.R.; Ferrante, R.J. and Dangond, F. (2005) Transcriptional therapy with the histone deacetylase inhibitor trichostatin A ameliorates experimental autoimmune encephalomyelitis. J. Neuroimmunol., 164(1-2), 10-21.
242. Gilbert, K.M. and Weigle, W.O. (1993) Th1 cell anergy and blockade in G1a phase of the cell cycle. J. Immunol., 151(3), 1245-1254.
243. Gilbert, K.M.; Wahid, R.; Fecher, N.P.; Freeman, J.P. and Fifer, E.K. (2000) Potential clinical use of butyric acid derivatives to induce antigen- specific T cell inactivation. J. Pharmacol. Exp. Ther., 294(3), 1146-1153.
244. Edens, R.E.; Dagtas, S. and Gilbert, K.M. (2006) Histone deacetylase inhibitors induce antigen specific anergy in lymphocytes: a comparative study. Int. Immunopharmacol., 6(11), 1673-1681.
245. Kanazawa, S. and Peterlin, B.M. (2001) Combinations of dominant-negative class II transactivator, p300 or CDK9 proteins block the expression of MHC II genes. Int. Immunol., 13(7), 951-958.
246. Fontes, J.D.; Kanazawa, S.; Jean, D. and Peterlin, B.M. (1999) Interactions between the class II transactivator and CREB binding protein increase transcription of major histocompatibility complex class II genes. Mol. Cell. Biol., 19(1), 941-947.
247. Masternak, K.; Muhlethaler-Mottet, A.; Villard, J.; Zufferey, M.; Steimle, V. and Reith, W. (2000) CIITA is a transcriptional coactivator that is recruited to MHC class II promoters by multiple synergistic interactions with an enhanceosome complex. Genes Dev., 14(9), 1156-1166.
248. Raval, A.; Howcroft, T.K.; Weissman, J.D.; Kirshner, S.; Zhu, X.S.; Yokoyama, K.; Ting, J. and Singer, D.S. (2001) Transcriptional coactivator, CIITA, is an acetyltransferase that bypasses a promoter requirement for TAF(II)250. Mol. Cell, 7(1), 105-115.
249. Masternak, K. and Reith, W. (2002) Promoter-specific functions of CIITA and the MHC class II enhanceosome in transcriptional activation. Embo J., 21(6), 1379-1388.
250. Zika, E.; Greer, S.F.; Zhu, X.S. and Ting, J.P. (2003) Histone deacetylase 1/mSin3A disrupts gamma interferon-induced CIITA function and major histocompatibility complex class II enhanceosome formation. Mol. Cell. Biol., 23(9), 3091-3102.
251. McKinsey, T.A.; Kuwahara, K.; Bezprozvannaya, S. and Olson, E.N. (2006) Class II histone deacetylases confer signal responsiveness to the ankyrin-repeat proteins ANKRA2 and RFXANK. Mol. Biol. Cell., 17(1), 438-447.
252. Wang, A.H.; Gregoire, S.; Zika, E.; Xiao, L.; Li, C.S.; Li, H.; Wright, K.L.; Ting, J.P. and Yang, X.J. (2005) Identification of the ankyrin repeat proteins ANKRA and RFXANK as novel partners of class IIa histone deacetylases. J. Biol. Chem., 280(32), 29117-29127.
253. Piskurich, J.F.; Lin, K.I.; Lin, Y., Wang, Y., Ting, J.P. and Calame, K. (2000) BLIMP-I mediates extinction of major histocompatibility class II transactivator expression in plasma cells. Nat. Immunol., 1(6), 526-532.
254. Ghosh, N.; Gyory, I.; Wright, G.; Wood, J. and Wright, K.L. (2001) Positive regulatory domain I binding factor 1 silences class II transactivator expression in multiple myeloma cells. J. Biol. Chem., 276(18), 15264-15268.
255. Chen, G.; Fernandez, J.; Mische, S. and Courey, A.J. (1999) A functional interaction between the histone deacetylase Rpd3 and the corepressor groucho in Drosophila development. Genes Dev., 13(17), 2218-2230.
256. Ren, B.; Chee, K.J.; Kim, T.H. and Maniatis, T. (1999) PRDI-BF1/Blimp-1 repression is mediated by corepressors of the Groucho family of proteins. Genes Dev., 13(1), 125-137.
257. Osborne, A.; Zhang, H.; Yang, W.M.; Seto, E. and Blanck, G. (2001) Histone deacetylase activity represses gamma interferon-inducible HLA- DR gene expression following the establishment of a DNase I- hypersensitive chromatin conformation. Mol. Cell. Biol., 21(19), 6495-6506.
258. Magner, W.J.; Kazim, A.L.; Stewart, C.; Romano, M.A.; Catalano, G.; Grande, C.; Keiser, N.; Santaniello, F. and Tomasi, T.B. (2000) Activation of MHC class I, II, and CD40 gene expression by histone deacetylase inhibitors. J. Immunol., 165(12), 7017-7024.
259. Brockmann, D.; Lehmkuhler, O.; Schmucker, U. and Esche, H. (2001) The histone acetyltransferase activity of PCAF cooperates with the brahma/ SWI2-related protein BRG-1 in the activation of the enhancer A of the MHC class I promoter. Gene, 277(1-2), 111-120.
260. Williams, K.; Ulvestad, E. and Antel, J.P. (1994) B7/BB-1 antigen expression on adult human microglia studied in vitro and in situ. Eur. J. Immunol., 24(12), 3031-3037.
261. Windhagen, A.; Newcombe, J.; Dangond, F.; Strand, C.; Woodroofe, M.N.; Cuzner, M.L. and Hafler, D.A. (1995) Expression of costimulatory molecules B7-1 (CD80), B7-2 (CD86), and interleukin 12 cytokine in multiple sclerosis lesions. J. Exp. Med., 182(6), 1985-1996.
262. Genc, K.; Dona, D.L. and Reder, A.T. (1997) Increased CD80(+) B cells in active multiple sclerosis and reversal by interferon beta-1b therapy. J. Clin. Invest., 99(11), 2664-2671.
263. Bohmig, G.A.; Krieger, P.M.; Saemann, M.D.; Wenhardt, C.; Pohanka, E. and Zlabinger, G.J. (1997) n-butyrate downregulates the stimulatory function of peripheral blood- derived antigen-presenting cells: a potential mechanism for modulating T-cell responses by short-chain fatty acids. Immunology, 92(2), 234-243.
264. Zlokovic, B.V. (2008) The blood-brain barrier in health and chronic neurodegenerative disorders. Neuron, 57(2), 178-201.
265. Yong, V.W.; Zabad, R.K.; Agrawal, S.; Goncalves Dasilva, A. and Metz, L.M. (2007) Elevation of matrix metalloproteinases (MMPs) in multiple sclerosis and impact of immunomodulators. J. Neurol. Sci., 259(1-2), 79-84.
266. Maeda, A. and Sobel, R.A. (1996) Matrix metalloproteinases in the normal human central nervous system, microglial nodules, and multiple sclerosis lesions. J. Neuropathol. Exp. Neurol., 55(3), 300-309.
267. Fiorino, A.S. and Zvibel, I. (1996) Disruption of cell-cell adhesion in the presence of sodium butyrate activates expression of the 92 kDa type IV collagenase in MDCK cells. Cell Biol. Int., 20(7), 489-499.
268. Vinodhkumar, R.; Song, Y.S.; Ravikumar, V.; Ramakrishnan, G. and Devaki, T. (2007) Depsipeptide a histone deacetlyase inhibitor down regulates levels of matrix metalloproteinases 2 and 9 mRNA and protein expressions in lung cancer cells (A549). Chem. Biol. Interact., 165(3), 220-229.
269. Aparicio, T.; Kermorgant, S.; Lewin, M.J. and Lehy, T. (1998) Effects of HGF on the production of matrix metalloproteinases by colonic cancer cells DHD/K12. C. R. Seances Soc. Biol. Fil., 192(2), 311-315.
270. Liu, L.-T.; Chang, H.-C.; Chiang, L.-C. and Hung, W.-C. (2003) Histone deacetylase inhibitor up-regulates RECK to inhibit MMP-2 activation and cancer cell invasion. Cancer Res., 63(12), 3069-3072.
271. Pender, S.L.; Quinn, J.J.; Sanderson, I.R. and MacDonald, T.T. (2000) Butyrate upregulates stromelysin-1 production by intestinal mesenchymal cells. Am. J. Physiol. Gastrointest. Liver Physiol., 279(5), G918-924.
272. Nasu, Y.; Nishida, K.; Miyazawa, S.; Komiyama, T.; Kadota, Y.; Abe, N.; Yoshida, A.; Hirohata, S.; Ohtsuka, A. and Ozaki, T. (2008) Trichostatin A, a histone deacetylase inhibitor, suppresses synovial inflammation and subsequent cartilage destruction in a collagen antibody-induced arthritis mouse model. Osteoarthritis Cartilage, 16(6), 723-732.
273. Emenaker, N.J. and Basson, M.D. (1998) Short chain fatty acids inhibit human (SW1116) colon cancer cell invasion by reducing urokinase plasminogen activator activity and stimulating TIMP-1 and TIMP-2 activities, rather than via MMP modulation. J. Surg. Res., 76(1), 41-46.
274. Emenaker, N.J.; Calaf, G.M.; Cox, D.; Basson, M.D. and Qureshi, N. (2001) Short-chain fatty acids inhibit invasive human colon cancer by modulating uPA, TIMP-1, TIMP-2, mutant p53, Bcl-2, Bax, p21 and PCNA protein expression in an in vitro cell culture model. J. Nutr., 131(11 Suppl), 3041S-3046S.
275. Thelen, P.; Schweyer, S.; Hemmerlein, B.; Wuttke, W.; Seseke, F. and Ringert, R.H. (2004) Expressional changes after histone deacetylase inhibition by valproic acid in LNCaP human prostate cancer cells. Int. J. Oncol., 24(1), 25-31.
276. Qian, X.; Ara, G.; Mills, E.; LaRochelle, W.J.; Lichenstein, H.S. and Jeffers, M. (2008) Activity of the histone deacetylase inhibitor belinostat (PXD101) in preclinical models of prostate cancer. Int. J. Cancer, 122(6), 1400-1410.
277. Young, D.A.; Billingham, O.; Sampieri, C.L.; Edwards, D.R. and Clark, I.M. (2005) Differential effects of histone deacetylase inhibitors on phorbol ester- and TGF-beta1 induced murine tissue inhibitor of metalloproteinases-1 gene expression. Febs J., 272(8), 1912-1926.
278. Mann, B.S.; Johnson, J.R.; Cohen, M.H.; Justice, R. and Pazdur, R. (2007) FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma. Oncologist, 12(10), 1247-1252.
279. Kim, T.Y.; Bang, Y.J. and Robertson, K.D. (2006) Histone deacetylase inhibitors for cancer therapy. Epigenetics, 1(1), 14-23.
280. Kelly, W.K.; Richon, V.M.; O'Connor, O.; Curley, T.; MacGregor-Curtelli, B.; Tong, W.; Klang, M.; Schwartz, L.; Richardson, S.; Rosa, E.; Drobnjak, M.; Cordon-Cordo, C.; Chiao, J.H.; Rifkind, R.; Marks, P.A. and Scher, H. (2003) Phase I clinical trial of histone deacetylase inhibitor: suberoylanilide hydroxamic acid administered intravenously. Clin. Cancer Res., 9(10 Pt 1), 3578-3588.
281. Kelly, W.K.; O'Connor, O.A.; Krug, L.M.; Chiao, J.H.; Heaney, M.; Curley, T.; MacGregore-Cortelli, B.; Tong, W.; Secrist, J.P.; Schwartz, L.; Richardson, S.; Chu, E.; Olgac, S.; Marks, P.A.; Scher, H. and Richon, V.M. (2005) Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer. J. Clin. Oncol., 23(17), 3923-3931.
282. Rubin, E.H.; Agrawal, N.G.; Friedman, E.J.; Scott, P.; Mazina, K.E.; Sun, L.; Du, L.; Ricker, J.L.; Frankel, S.R.; Gottesdiener, K.M.; Wagner, J.A. and Iwamoto, M. (2006) A study to determine the effects of food and multiple dosing on the pharmacokinetics of vorinostat given orally to patients with advanced cancer. Clin. Cancer Res., 12(23), 7039-7045.
283. Richardson, P.; Mitsiades, C.; Colson, K.; Reilly, E.; McBride, L.; Chiao, J.; Sun, L.; Ricker, J.; Rizvi, S.; Oerth, C.; Atkins, B.; Fearen, I.; Anderson, K. and Siegel, D. (2008) Phase I trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) in patients with advanced multiple myeloma. Leuk. Lymphoma, 49(3), 502-507.
284. Garcia-Manero, G.; Yang, H.; Bueso-Ramos, C.; Ferrajoli, A.; Cortes, J.; Wierda, W.G.; Faderl, S.; Koller, C.; Morris, G.; Rosner, G.; Loboda, A.; Fantin, V.R.; Randolph, S.S.; Hardwick, J.S.; Reilly, J.F.; Chen, C.; Ricker, J.L.; Secrist, J.P.; Richon, V.M.; Frankel, S.R. and Kantarjian, H.M. (2008) Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes. Blood, 111(3), 1060-1066.
285. Olsen, E.A.; Kim, Y.H.; Kuzel, T.M.; Pacheco, T.R.; Foss, F.M.; Parker, S.; Frankel, S.R.; Chen, C.; Ricker, J.L.; Arduino, J.M. and Duvic, M. (2007) Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma. J. Clin. Oncol., 25(21), 3109-3115.
286. Duvic, M.; Talpur, R.; Ni, X.; Zhang, C.; Hazarika, P.; Kelly, C.; Chiao, J.H.; Reilly, J.F.; Ricker, J.L.; Richon, V.M. and Frankel, S.R. (2007) Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL). Blood, 109(1), 31-39.
287. Crump, M.; Coiffier, B.; Jacobsen, E.D.; Sun, L.; Ricker, J.L.; Xie, H.; Frankel, S.R.; Randolph, S.S. and Cheson, B.D. (2008) Phase II trial of oral vorinostat (suberoylanilide hydroxamic acid) in relapsed diffuse large-B-cell lymphoma. Ann. Oncol., 19(5), 964-969.
288. Modesitt, S.C.; Sill, M.; Hoffman, J.S. and Bender, D.P. (2008) A phase II study of vorinostat in the treatment of persistent or recurrent epithelial ovarian or primary peritoneal carcinoma: A Gynecologic Oncology Group study. Gynecol. Oncol. 109(2), 182-186.
289. Blumenschein, G.R.Jr.; Kies, M.S.; Papadimitrakopoulou, V.A.; Lu, C.; Kumar, A.J.; Ricker, J.L.; Chiao, J.H.; Chen, C. and Frankel, S.R. (2008) Phase II trial of the histone deacetylase inhibitor vorinostat (Zolinza, suberoylanilide hydroxamic acid, SAHA) in patients with recurrent and/or metastatic head and neck cancer. Invest. New Drugs, 26(1), 81-87.
290. Vansteenkiste, J.; Cutsem, E.V.; Dumez, H.; Chen, C.; Ricker, J.L.; Randolph, S.S. and Schoffski, P. (2008) Early phase II trial of oral vorinostat in relapsed or refractory breast, colorectal, or non-small cell lung cancer. Invest. New Drugs, 26(5), 483-488.
291. Krug, L.M.; Curley, T.; Schwartz, L.; Richardson, S.; Marks, P.; Chiao, J. and Kelly, W.K. (2006) Potential role of histone deacetylase inhibitors in mesothelioma: clinical experience with suberoy-lanilide hydroxamic acid. Clin. Lung Cancer, 7(4), 257-261.
292. Ramalingam, S.S.; Parise, R.A.; Ramanathan, R.K.; Lagattuta, T.F.; Musguire, L.A.; Stoller, R.G.; Potter, D.M.; Argiris, A.E.; Zwiebel, J.A.; Egorin, M.J. and Belani, C.P. (2007) Phase I and pharmacokinetic study of vorinostat, a histone deacetylase inhibitor, in combination with carboplatin and paclitaxel for advanced solid malignancies. Clin. Cancer Res., 13(12), 3605-3610.
293. Gilbert, J.; Baker, S.D.; Bowling, M.K.; Grochow, L.; Figg, W.D.; Zabelina, Y.; Donehower, R.C. and Carducci, M.A. (2001) A phase I dose escalation and bioavailability study of oral sodium phenylbutyrate in patients with refractory solid tumor malignancies. Clin. Cancer Res., 7(8), 2292-2300.
294. Carducci, M.A.; Gilbert, J.; Bowling, M.K.; Noe, D.; Eisenberger, M.A.; Sinibaldi, V.; Zabelina, Y.; Chen, T.L.; Grochow, L.B. and Donehower, R.C. (2001) A Phase I clinical and pharmacological evaluation of sodium phenylbutyrate on an 120-h infusion schedule. Clin. Cancer Res., 7(10), 3047-3055.
295. Camacho, L.H.; Olson, J.; Tong, W.P.; Young, C.W.; Spriggs, D.R. and Malkin, M.G. (2007) Phase I dose escalation clinical trial of phenylbutyrate sodium administered twice daily to patients with advanced solid tumors. Invest. New Drugs, 25(2), 131-138.
296. Brahe, C.; Vitali, T.; Tiziano, F.D.; Angelozzi, C.; Pinto, A.M.; Borgo, F.; Moscato, U.; Bertini, E.; Mercuri, E. and Neri, G. (2005) Phenylbutyrate increases SMN gene expression in spinal muscular atrophy patients. Eur. J. Hum. Genet., 13(2), 256-259.
297. Mercuri, E.; Bertini, E.; Messina, S.; Pelliccioni, M.; D'Amico, A.; Colitto, F.; Mirabella, M.; Tiziano, F.D.; Vitali, T.; Angelozzi, C.; Kinali, M.; Main, M. and Brahe, C. (2004) Pilot trial of phenylbutyrate in spinal muscular atrophy. Neuromuscul. Disord., 14(2), 130-135.
298. Mercuri, E.; Bertini, E.; Messina, S.; Solari, A.; D'Amico, A.; Angelozzi, C.; Battini, R.; Berardinelli, A.; Boffi, P.; Bruno, C.; Cini, C.; Colitto, F.; Kinali, M.; Minetti, C.; Mongini, T.; Morandi, L.; Neri, G.; Orcesi, S.; Pane, M.; Pelliccioni, M.; Pini, A.; Tiziano, F.D.; Villanova, M.; Vita, G. and Brahe, C. (2007) Randomized, double-blind, placebo-controlled trial of phenylbutyrate in spinal muscular atrophy. Neurology, 68(1), 51-55.
299. Hogarth, P.; Lovrecic, L. and Krainc, D. (2007) Sodium phenylbutyrate in Huntington's disease: a dose-finding study. Mov. Disord., 22(13), 1962-1964.
300. Zeitlin, P.L.; Diener-West, M.; Rubenstein, R.C.; Boyle, M.P.; Lee, C.K. and Brass-Ernst, L. (2002) Evidence of CFTR function in cystic fibrosis after systemic administration of 4-phenylbutyrate. Mol. Ther., 6(1), 119-126.
301. Phuphanich, S.; Baker, S.D.; Grossman, S.A.; Carson, K.A.; Gilbert, M.R.; Fisher, J.D. and Carducci, M.A. (2005) Oral sodium phenylbutyrate in patients with recurrent malignant gliomas: a dose escalation and pharmacologic study. Neuro. Oncol., 7(2), 177-182.
302. Sung, M.W. and Waxman, S. (2007) Combination of cytotoxic-differentiation therapy with 5-fluorouracil and phenylbutyrate in patients with advanced colorectal cancer. Anticancer Res., 27(2), 995-1001.
303. Maslak, P.; Chanel, S.; Camacho, L.H.; Soignet, S.; Pandolfi, P.P.; Guernah, I.; Warrell, R. and Nimer, S. (2006) Pilot study of combination transcriptional modulation therapy with sodium phenylbutyrate and 5-azacytidine in patients with acute myeloid leukemia or myelodysplastic syndrome. Leukemia, 20(2), 212-217.
304. Rudek, M.A.; Zhao, M.; He, P.; Hartke, C.; Gilbert, J.; Gore, S.D.; Carducci, M.A. and Baker, S.D. (2005) Pharmacokinetics of 5-azacitidine administered with phenylbutyrate in patients with refractory solid tumors or hematologic malignancies. J. Clin. Oncol., 23(17), 3906-3911.
305. Atmaca, A.; Al-Batran, S.E.; Maurer, A.; Neumann, A.; Heinzel, T.; Hentsch, B.; Schwarz, S.E.; Hovelmann, S.; Gottlicher, M.; Knuth, A. and Jager, E. (2007) Valproic acid (VPA) in patients with refractory advanced cancer: a dose escalating phase I clinical trial. Br. J. Cancer, 97(2), 177-182.
306. Candelaria, M.; Gallardo-Rincon, D.; Arce, C.; Cetina, L.; Aguilar-Ponce, J.L.; Arrieta, O.; Gonzalez-Fierro, A.; Chavez-Blanco, A.; de la Cruz-Hernandez, E.; Camargo, M.F.; Trejo-Becerril, C.; Perez-Cardenas, E.; Perez-Plasencia, C.; Taja-Chayeb, L.; Wegman-Ostrosky, T.; Revilla-Vazquez, A. and Duenas-Gonzalez, A. (2007) A phase II study of epigenetic therapy with hydralazine and magnesium valproate to overcome chemotherapy resistance in refractory solid tumors. Ann. Oncol., 18(9), 1529-1538.
307. Arce, C.; Perez-Plasencia, C.; Gonzalez-Fierro, A.; de la Cruz-Hernandez, E.; Revilla-Vazquez, A.; Chavez-Blanco, A.; Trejo-Becerril, C.; Perez-Cardenas, E.; Taja-Chayeb, L.; Bargallo, E.; Villarreal, P.; Ramirez, T.; Vela, T.; Candelaria, M.; Camargo, M.F.; Robles, E. and Duenas-Gonzalez, A. (2006) A proof-of-principle study of epigenetic therapy added to neoadjuvant doxorubicin cyclophosphamide for locally advanced breast cancer. PLoS ONE, 1 e98.
308. Blum, W.; Klisovic, R.B.; Hackanson, B.; Liu, Z.; Liu, S.; Devine, H.; Vukosavljevic, T.; Huynh, L.; Lozanski, G.; Kefauver, C.; Plass, C.; Devine, S.M.; Heerema, N.A.; Murgo, A.; Chan, K.K.; Grever, M.R.; Byrd, J.C. and Marcucci, G. (2007) Phase I study of decitabine alone or in combination with valproic acid in acute myeloid leukemia. J. Clin. Oncol., 25(25), 3884-3891.
309. Garcia-Manero, G.; Kantarjian, H.M.; Sanchez-Gonzalez, B.; Yang, H.; Rosner, G.; Verstovsek, S.; Rytting, M.; Wierda, W.G.; Ravandi, F.; Koller, C.; Xiao, L.; Faderl, S.; Estrov, Z.; Cortes, J.; O'Brien, S.; Estey, E.; Bueso-Ramos, C.; Fiorentino, J.; Jabbour, E. and Issa, J.P. (2006) Phase 1/2 study of the combination of 5-aza-2′-deoxycytidine with valproic acid in patients with leukemia. Blood, 108(10), 3271-3279.
310. Bug, G.; Ritter, M.; Wassmann, B.; Schoch, C.; Heinzel, T.; Schwarz, K.; Romanski, A.; Kramer, O.H.; Kampfmann, M.; Hoelzer, D.; Neubauer, A.; Ruthardt, M. and Ottmann, O.G. (2005) Clinical trial of valproic acid and all-trans retinoic acid in patients with poor-risk acute myeloid leukemia. The histone deacetylase (HDAC) inhibitor valproic acid as monotherapy or in combination with all-trans retinoic acid in patients with acute myeloid leukemia. Cancer, 104(12), 2717-2725.
311. Kuendgen, A.; Schmid, M.; Schlenk, R.; Knipp, S.; Hildebrandt, B.; Steidl, C.; Germing, U.; Haas, R.; Dohner, H. and Gattermann, N. (2006) The histone deacetylase (HDAC) inhibitor valproic acid as monotherapy or in combination with all-trans retinoic acid in patients with acute myeloid leukemia. Cancer, 106(1), 112-119.
312. Kuendgen, A.; Knipp, S.; Fox, F.; Strupp, C.; Hildebrandt, B.; Steidl, C.; Germing, U.; Haas, R. and Gattermann, N. (2005) Results of a phase 2 study of valproic acid alone or in combination with all-trans retinoic acid in 75 patients with myelodysplastic syndrome and relapsed or refractory acute myeloid leukemia. Ann. Hematol., 84(Suppl 1), 61-66.
313. Pilatrino, C.; Cilloni, D.; Messa, E.; Morotti, A.; Giugliano, E.; Pautasso, M.; Familiari, U.; Cappia, S.; Pelicci, P.G.; Lo Coco, F.; Saglio, G. and Guerrasio, A. (2005) Increase in platelet count in older, poor-risk patients with acute myeloid leukemia or myelodysplastic syndrome treated with valproic acid and all-trans retinoic acid. Cancer, 104(1), 101-109.
314. Soriano, A.O.; Yang, H.; Faderl, S.; Estrov, Z.; Giles, F.; Ravandi, F.; Cortes, J.; Wierda, W.G.; Ouzounian, S.; Quezada, A.; Pierce, S.; Estey, E.H.; Issa, J.P.; Kantarjian, H.M. and Garcia-Manero, G. (2007) Safety and clinical activity of the combination of 5-azacytidine, valproic acid and all-trans retinoic acid in acute myeloid leukemia and myelodysplastic syndrome. Blood, 110(7), 2302-2308.
315. Münster, P.; Marchion, D.; Bicaku, E.; Schmitt, M.; Lee, J.H.; DeConti, R.; Simon, G.; Fishman, M.; Minton, S.; Garrett, C.; Chiappori, A.; Lush, R.; Sullivan, D. and Daud, A. (2007) Phase I trial of histone deacetylase inhibition by valproic acid followed by the topoisomerase II inhibitor epirubicin in advanced solid tumors: a clinical and translational study. J. Clin. Oncol., 25(15), 1979-1985.
316. Patnaik, A.; Rowinsky, E.K.; Villalona, M.A.; Hammond, L.A.; Britten, C.D.; Siu, L.L.; Goetz, A.; Felton, S.A.; Burton, S.; Valone, F.H. and Eckhardt, S.G. (2002) A phase I study of pivaloyloxymethyl butyrate, a prodrug of the differentiating agent butyric acid, in patients with advanced solid malignancies. Clin. Cancer Res., 8(7), 2142-2148.
317. Reid, T.; Valone, F.; Lipera, W.; Irwin, D.; Paroly, W.; Natale, R.; Sreedharan, S.; Keer, H.; Lum, B.; Scappaticci, F. and Bhatnagar, A. (2004) Phase II trial of the histone deacetylase inhibitor pivaloyloxymethyl butyrate (Pivanex, AN-9) in advanced non-small cell lung cancer. Lung Cancer, 45(3), 381-386.
318. Byrd, J.C.; Marcucci, G.; Parthun, M.R.; Xiao, J.J.; Klisovic, R.B.; Moran, M.; Lin, T.S.; Liu, S.; Sklenar, A.R.; Davis, M.E.; Lucas, D.M.; Fischer, B.; Shank, R.; Tejaswi, S.L.; Binkley, P.; Wright, J.; Chan, K.K. and Grever, M.R. (2005) A phase 1 and pharmacodynamic study of depsipeptide (FK228) in chronic lymphocytic leukemia and acute myeloid leukemia. Blood, 105(3), 959-967.
319. Fouladi, M.; Furman, W.L.; Chin, T.; Freeman, B.B.3rd.; Dudkin, L.; Stewart, C.F.; Krailo, M.D.; Speights, R.; Ingle, A.M.; Houghton, P.J.; Wright, J.; Adamson, P.C. and Blaney, S.M. (2006) Phase I study of depsipeptide in pediatric patients with refractory solid tumors: a Children's Oncology Group report. J. Clin. Oncol., 24(22), 3678-3685.
320. Marshall, J.L.; Rizvi, N.; Kauh, J.; Dahut, W.; Figuera, M.; Kang, M.H.; Figg, W.D.; Wainer, I.; Chaissang, C.; Li, M.Z. and Hawkins, M.J. (2002) A phase I trial of depsipeptide (FR901228) in patients with advanced cancer. J. Exp. Ther. Oncol., 2(6), 325-332.
321. Sandor, V.; Bakke, S.; Robey, R.W.; Kang, M.H.; Blagosklonny, M.V.; Bender, J.; Brooks, R.; Piekarz, R.L.; Tucker, E.; Figg, W.D.; Chan, K.K.; Goldspiel, B.; Fojo, A.T.; Balcerzak, S.P. and Bates, S.E. (2002) Phase I trial of the histone deacetylase inhibitor, depsipeptide (FR901228, NSC 630176), in patients with refractory neoplasms. Clin. Cancer Res., 8(3), 718-728.
322. Klimek, V.M.; Fircanis, S.; Maslak, P.; Guernah, I.; Baum, M.; Wu, N.; Panageas, K.; Wright, J.J.; Pandolfi, P.P. and Nimer, S.D. (2008) Tolerability, pharmacodynamics, and pharmacokinetics studies of depsipeptide (romidepsin) in patients with acute myelogenous leukemia or advanced myelodysplastic syndromes. Clin. Cancer Res., 14(3), 826-832.
323. Stadler, W.M.; Margolin, K.; Ferber, S.; McCulloch, W. and Thompson, J.A. (2006) A phase II study of depsipeptide in refractory metastatic renal cell cancer. Clin. Genitourin. Cancer, 5(1), 57-60.
324. Piekarz, R.L.; Frye, A.R.; Wright, J.J.; Steinberg, S.M.; Liewehr, D.J.; Rosing, D.R.; Sachdev, V.; Fojo, T. and Bates, S.E. (2006) Cardiac studies in patients treated with depsipeptide, FK228, in a phase II trial for T-cell lymphoma. Clin. Cancer Res., 12(12), 3762-3773.
325. Shah, M.H.; Binkley, P.; Chan, K.; Xiao, J.; Arbogast, D.; Collamore, M.; Farra, Y.; Young, D. and Grever, M. (2006) Cardiotoxicity of histone deacetylase inhibitor depsipeptide in patients with metastatic neuroendocrine tumors. Clin. Cancer Res., 12(13), 3997-4003.
326. Schrump, D.S.; Fischette, M.R.; Nguyen, D.M.; Zhao, M.; Li, X.; Kunst, T.F.; Hancox, A.; Hong, J.A.; Chen, G.A.; Kruchin, E.; Wright, J.J.; Rosing, D.R.; Sparreboom, A.; Figg, W.D. and Steinberg, S.M. (2008) Clinical and molecular responses in lung cancer patients receiving Romidepsin. Clin. Cancer Res., 14(1), 188-198.
327. Prakash, S.; Foster, B.J.; Meyer, M.; Wozniak, A.; Heilbrun, L.K.; Flaherty, L.; Zalupski, M.; Radulovic, L.; Valdivieso, M. and Lo-Russo, P.M. (2001) Chronic oral administration of CI-994: a phase 1 study. Invest. New Drugs, 19(1), 1-11.
328. Nemunaitis, J.J.; Orr, D.; Eager, R.; Cunningham, C.C.; Williams, A.; Mennel, R.; Grove, W. and Olson, S. (2003) Phase I study of oral CI-994 in combination with gemcitabine in treatment of patients with advanced cancer. Cancer J., 9(1), 58-66.
329. Undevia, S.D.; Kindler, H.L.; Janisch, L.; Olson, S.C.; Schilsky, R.L.; Vogelzang, N.J.; Kimmel, K.A.; Macek, T.A. and Ratain, M.J. (2004) A phase I study of the oral combination of CI-994, a putative histone deacetylase inhibitor, and capecitabine. Ann. Oncol., 15(11), 1705-1711.
330. Pauer, L.R.; Olivares, J.; Cunningham, C.; Williams, A.; Grove, W.; Kraker, A.; Olson, S. and Nemunaitis, J. (2004) Phase I study of oral CI-994 in combination with carboplatin and paclitaxel in the treatment of patients with advanced solid tumors. Cancer Invest., 22(6), 886-896.
331. Kummar, S.; Gutierrez, M.; Gardner, E.R.; Donovan, E.; Hwang, K.; Chung, E.J.; Lee, M.J.; Maynard, K.; Kalnitskiy, M.; Chen, A.; Melillo, G.; Ryan, Q.C.; Conley, B.; Figg, W.D.; Trepel, J.B.; Zwiebel, J.; Doroshow, J.H. and Murgo, A.J. (2007) Phase I trial of MS-275, a histone deacetylase inhibitor, administered weekly in refractory solid tumors and lymphoid malignancies. Clin. Cancer Res., 13(18 Pt 1), 5411-5417.
332. Ryan, Q.C.; Headlee, D.; Acharya, M.; Sparreboom, A.; Trepel, J.B.; Ye, J.; Figg, W.D.; Hwang, K.; Chung, E.J.; Murgo, A.; Melillo, G.; Elsayed, Y.; Monga, M.; Kalnitskiy, M.; Zwiebel, J. and Sausville, E.A. (2005) Phase I and pharmacokinetic study of MS-275, a histone deacetylase inhibitor, in patients with advanced and refractory solid tumors or lymphoma. J. Clin. Oncol., 23(17), 3912-3922.
333. Gojo, I.; Jiemjit, A.; Trepel, J.B.; Sparreboom, A.; Figg, W.D.; Rollins, S.; Tidwell, M.L.; Greer, J.; Chung, E.J.; Lee, M.J.; Gore, S.D.; Sausville, E.A.; Zwiebel, J. and Karp, J.E. (2007) Phase 1 and pharmacologic study of MS-275, a histone deacetylase inhibitor, in adults with refractory and relapsed acute leukemias. Blood, 109(7), 2781-2790.
334. Acharya, M.R.; Karp, J.E.; Sausville, E.A.; Hwang, K.; Ryan, Q.; Gojo, I.; Venitz, J.; Figg, W.D. and Sparreboom, A. (2006) Factors affecting the pharmacokinetic profile of MS-275, a novel histone deacetylase inhibitor, in patients with cancer. Invest. New Drugs, 24(5), 367-375.
335. Mayo, M.W.; Denlinger, C.E.; Broad, R.M.; Yeung, F.; Reilly, E.T.; Shi, Y. and Jones, D.R. (2003) Ineffectiveness of histone deacetylase inhibitors to induce apoptosis involves the transcriptional activation of NF-kappa B through the Akt pathway. J. Biol.Chem., 278(21), 18980-18989.
336. Liu, Y.; Denlinger, C.E.; Rundall, B.K.; Smith, P.W. and Jones, D.R. (2006) Suberoylanilide hydroxamic acid induces Akt-mediated phosphorylation of p300, which promotes acetylation and transcriptional activation of RelA/p65. J. Biol. Chem., 281(42), 31359-31368.
337. Greco, R.; Latini, G.; Chiarelli, F.; Iannetti, P. and Verrotti, A. (2005) Leptin, ghrelin, and adiponectin in epileptic patients treated with valproic acid. Neurology, 65(11), 1808-1809.
338. Pylvanen, V.; Knip, M.; Pakarinen, A.J.; Turkka, J.; Kotila, M.; Rattya, J.; Myllyla, V.V. and Isojarvi, J.I. (2003) Fasting serum insulin and lipid levels in men with epilepsy. Neurology, 60(4), 571-574.
339. Pylvanen, V.; Pakarinen, A.; Knip, M. and Isojarvi, J. (2006) Characterization of insulin secretion in Valproate-treated patients with epilepsy. Epilepsia, 47(9), 1460-1464.
340. Pylvanen, V.; Pakarinen, A.; Knip, M. and Isojarvi, J. (2006) Insulin-related metabolic changes during treatment with valproate in patients with epilepsy. Epilepsy Behav., 8(3), 643-648.
341. Tan, H.; Orbak, Z.; Kantarci, M.; Kocak, N. and Karaca, L. (2005) Valproate-induced insulin resistance in prepubertal girls with epilepsy. J. Pediatr. Endocrinol. Metab., 18(10), 985-989.
342. Verrotti, A.; di Corcia, G.; Salladini, C.; Trotta, D.; Morgese, G. and Chiarelli, F. (2003) Serum insulin and leptin levels and valproate-associated obesity. Epilepsia, 44(12), 1606.
343. Lagace, D.C. and Nachtigal, M.W. (2004) Inhibition of histone deacetylase activity by valproic acid blocks adipogenesis. J. Biol. Chem., 279(18), 18851-18860.
344. Salminen, A.; Tapiola, T.; Korhonen, P. and Suuronen, T. (1998) Neuronal apoptosis induced by histone deacetylase inhibitors. Brain Res. Mol. Brain Res., 61(1-2), 203-206.
345. Suuronen, T.; Huuskonen, J.; Pihlaja, R.; Kyrylenko, S. and Salminen, A. (2003) Regulation of microglial inflammatory response by histone deacetylase inhibitors. J. Neurochem., 87(2), 407-416.
346. Kim, Y.K.; Lee, E.K.; Kang, J.K.; Kim, J.A.; You, J.S.; Park, J.H.; Seo, D.W.; Hwang, J.W.; Kim, S.N.; Lee, H.Y.; Lee, H.W. and Han, J.W. (2006) Activation of NF-kappaB by HDAC inhibitor apicidin through Sp1-dependent de novo protein synthesis: its implication for resistance to apoptosis. Cell Death Differ., 13(12), 2033-2041.
347. Teckman, J.H. (2004) Lack of effect of oral 4-phenylbutyrate on serum alpha-1-antitrypsin in patients with alpha-1-antitrypsin deficiency: a preliminary study. J. Pediatr. Gastroenterol. Nutr., 39(1), 34-37.
348. Nambiar, M.P.; Warke, V.G.; Fisher, C.U. and Tsokos, G.C. (2002) Effect of trichostatin A on human T cells resembles signaling abnormalities in T cells of patients with systemic lupus erythematosus: a new mechanism for TCR zeta chain deficiency and abnormal signaling. J. Cell. Biochem., 85(3), 459-469.
349. Zhou, Y.; Eppenberger-Castori, S.; Eppenberger, U. and Benz, C.C. (2005) The NFkappaB pathway and endocrine-resistant breast cancer. Endocr. Relat. Cancer., 12(Suppl 1), S37-S46.
350. Zhou, Y.; Yau, C.; Gray, J.W.; Chew, K.; Dairkee, S.H.; Moore, D.H.; Eppenberger, U.; Eppenberger-Castori, S. and Benz, C.C. (2007) Enhanced NF kappa B and AP-1 transcriptional activity associated with antiestrogen resistant breast cancer. BMC Cancer, 7, 59.
351. Kovacs, J.J.; Murphy, P.J.; Gaillard, S.; Zhao, X.; Wu, J.T.; Nicchitta, C.V.; Yoshida, M.; Toft, D.O.; Pratt, W.B. and Yao, T.P. (2005) HDAC6 regulates Hsp90 acetylation and chaperone-dependent activation of glucocorticoid receptor. Mol. Cell, 18(5), 601-607.
352. Boyault, C.; Gilquin, B.; Zhang, Y.; Rybin, V.; Garman, E.; Meyer-Klaucke, W.; Matthias, P.; Muller, C.W. and Khochbin, S. (2006) HDAC6-p97/VCP controlled polyubiquitin chain turnover. Embo J., 25(14), 3357-3366.
353. Boyault, C.; Zhang, Y.; Fritah, S.; Caron, C.; Gilquin, B.; Kwon, S.H.; Garrido, C.; Yao, T.P.; Vourc'h, C. and Matthias, P. and Khochbin, S. (2007) HDAC6 controls major cell response pathways to cytotoxic accumulation of protein aggregates. Genes Dev., 21(17), 2172-2181.
354. Gao, Y.S.; Hubbert, C.C.; Lu, J.; Lee, Y.S.; Lee, J.Y. and Yao, T.P. (2007) Histone deacetylase 6 regulates growth factor-induced actin remodeling and endocytosis. Mol. Cell. Biol., 27(24), 8637-8647.
355. Fiskus, W.; Ren, Y.; Mohapatra, A.; Bali, P.; Mandawat, A.; Rao, R.; Herger, B.; Yang, Y.; Atadja, P.; Wu, J. and Bhalla, K. (2007) Hydroxamic acid analogue histone deacetylase inhibitors attenuate estrogen receptor-alpha levels and transcriptional activity: a result of hyperacetylation and inhibition of chaperone function of heat shock protein 90. Clin. Cancer Res., 13(16), 4882-4890.
356. Wang, Y.; Wang, S.Y.; Zhang, X.H.; Zhao, M.; Hou, C.M.; Xu, Y.J.; Du, Z.Y. and Yu, X.D. (2007) FK228 inhibits Hsp90 chaperone function in K562 cells via hyperacetylation of Hsp70. Biochem. Biophys. Res. Commun., 356(4), 998-1003.
357. Scroggins, B.T.; Robzyk, K.; Wang, D.; Marcu, M.G.; Tsutsumi, S.; Beebe, K.; Cotter, R.J.; Felts, S.; Toft, D.; Karnitz, L.; Rosen, N. and Neckers, L. (2007) An acetylation site in the middle domain of Hsp90 regulates chaperone function. Mol. Cell, 25(1), 151-159.
358. Edwards, A.; Li, J.; Atadja, P.; Bhalla, K. and Haura, E.B. (2007) Effect of the histone deacetylase inhibitor LBH589 against epidermal growth factor receptor-dependent human lung cancer cells. Mol. Cancer Ther., 6(9), 2515-2524.
359. Bali, P.; Pranpat, M.; Bradner, J.; Balasis, M.; Fiskus, W.; Guo, F.; Rocha, K.; Kumaraswamy, S.; Boyapalle, S.; Atadja, P.; Seto, E. and Bhalla, K. (2005) Inhibition of histone deacetylase 6 acetylates and disrupts the chaperone function of heat shock protein 90: a novel basis for antileukemia activity of histone deacetylase inhibitors. J. Biol. Chem., 280(29), 26729-26734.
360. Kong, X.; Lin, Z.; Liang, D.; Fath, D.; Sang, N. and Caro, J. (2006) Histone deacetylase inhibitors induce VHL and ubiquitin-independent proteasomal degradation of hypoxia-inducible factor 1alpha. Mol. Cell. Biol., 26(6), 2019-2028.
361. Johnson, C.A.; White, D.A.; Lavender, J.S.; O'Neill, L.P. and Turner, B.M. (2002) Human class I histone deacetylase complexes show enhanced catalytic activity in the presence of ATP and co-immunoprecipitate with the ATP-dependent chaperone protein Hsp70. J. Biol. Chem., 277(11), 9590-9597.
362. Liu, X.L.; Done, S.C.; Yan, K.; Kilpelainen, P.; Pikkarainen, T. and Tryggvason, K. (2004) Defective trafficking of nephrin missense mutants rescued by a chemical chaperone. J. Am. Soc. Nephrol., 15(7), 1731-1738.
363. Yam, G.H.; Roth, J. and Zuber, C. (2007) 4-Phenylbutyrate rescues trafficking incompetent mutant alpha-galactosidase A without restoring its functionality. Biochem. Biophys. Res. Commun., 360(2), 375-380.
364. Datta, R.; Waheed, A.; Shah, G.N. and Sly, W.S. (2007) Signal sequence mutation in autosomal dominant form of hypoparathyroidism induces apoptosis that is corrected by a chemical chaperone. Proc. Natl. Acad. Sci. USA, 104(50), 19989-19994.
365. Watanabe, N. and Lam, E. (2008) BAX inhibitor-1 modulates endoplasmic reticulum stress-mediated programmed cell death in Arabidopsis. J. Biol. Chem., 283(6), 3200-3210.
366. Corson, T.W.; Woo, K.K.; Li, P.P. and Warsh, J.J. (2004) Cell-type specific regulation of calreticulin and Bcl-2 expression by mood stabilizer drugs. Eur. Neuropsychopharmacol., 14(2), 143-150.
367. Wang, J.F.; Bown, C.D.; Chen, B. and Young, L.T. (2001) Identification of mood stabilizer-regulated genes by differential-display PCR. Int. J. Neuropsychopharmacol., 4(1), 65-74.
368. Kim, H.J.; Rowe, M.; Ren, M.; Hong, J.S.; Chen, P.S. and Chuang, D.M. (2007) Histone deacetylase inhibitors exhibit antiinflammatory and neuroprotective effects in a rat permanent ischemic model of stroke: multiple mechanisms of action. J. Pharmacol. Exp. Ther., 321(3), 892-901.
369. Ren, M.; Leng, Y.; Jeong, M.; Leeds, P.R. and Chuang, D.M. (2004) Valproic acid reduces brain damage induced by transient focal cerebral ischemia in rats: potential roles of histone deacetylase inhibition and heat shock protein induction. J. Neurochem., 89(6), 1358-1367.
370. Morland, C.; Boldingh, K.A.; Iversen, E.G. and Hassel, B. (2004) Valproate is neuroprotective against malonate toxicity in rat striatum: an association with augmentation of high-affinity glutamate uptake. J. Cereb. Blood Flow Metab., 24(11), 1226-1234.
371. Inden, M.; Kitamura, Y.; Takeuchi, H.; Yanagida, T.; Takata, K.; Kobayashi, Y.; Taniguchi, T.; Yoshimoto, K.; Kaneko, M.; Okuma, Y.; Taira, T.; Ariga, H. and Shimohama, S. (2007) Neurodegeneration of mouse nigrostriatal dopaminergic system induced by repeated oral administration of rotenone is prevented by 4-phenylbutyrate, a chemical chaperone. J. Neurochem., 101(6), 1491-1504.
372. Pan, T.; Li, X.; Xie, W.; Jankovic, J. and Le, W. (2005) Valproic acid-mediated Hsp70 induction and anti-apoptotic neuroprotection in SH-SY5Y cells. FEBS Lett., 579(30), 6716-6720.
373. Hiroi, T.; Wei, H.; Hough, C.; Leeds, P. and Chuang, D.M. (2005) Protracted lithium treatment protects against the ER stress elicited by thapsigargin in rat PC12 cells: roles of intracellular calcium, GRP78 and Bcl-2. Pharmacogenomics J., 5(2), 102-111.
374. Singh, O.V.; Vij, N.; Mogayzel, P.J.Jr.; Jozwik, C.; Pollard, H.B. and Zeitlin, P.L. (2006) Pharmacoproteomics of 4-phenylbutyrate-treated IB3-1 cystic fibrosis bronchial epithelial cells. J. Proteome Res., 5(3), 562-571.
375. Rubenstein, R.C. and Zeitlin, P.L. (1998) A pilot clinical trial of oral sodium 4-phenylbutyrate (Buphenyl) in deltaF508-homozygous cystic fibrosis patients: partial restoration of nasal epithelial CFTR function. Am. J. Respir. Crit. Care Med., 157(2), 484-490.
376. Rubenstein, R.C. and Lyons, B.M. (2001) Sodium 4-phenylbutyrate downregulates HSC70 expression by facilitating mRNA degradation. Am. J. Physiol. Lung Cell. Mol. Physiol., 281(1), L43-51.
377. Rubenstein, R.C.; Egan, M.E. and Zeitlin, P.L. (1997) In vitro pharmacologic restoration of CFTR-mediated chloride transport with sodium 4-phenylbutyrate in cystic fibrosis epithelial cells containing delta F508-CFTR. J. Clin. Invest., 100(10), 2457-2465.
378. Lim, M., McKenzie, K., Floyd, A.D., Kwon, E. and Zeitlin, P.L. (2004) Modulation of deltaF508 cystic fibrosis transmembrane regulator trafficking and function with 4-phenylbutyrate and flavonoids. Am. J. Respir. Cell Mol. Biol., 31(3), 351-357.
379. Kontopoulos, E.; Parvin, J.D. and Feany, M.B. (2006) Alpha-synuclein acts in the nucleus to inhibit histone acetylation and promote neurotoxicity. Hum. Mol. Genet., 15(20), 3012-3023.
380. Choo-Kang, L.R. and Zeitlin, P.L. (2001) Induction of HSP70 promotes DeltaF508 CFTR trafficking. Am. J. Physiol. Lung Cell. Mol. Physiol., 281(1), L58-68.
381. Cheong, N.; Madesh, M.; Gonzales, L.W.; Zhao, M.; Yu, K.; Ballard, P.L. and Shuman, H. (2006) Functional and trafficking defects in ATP binding cassette A3 mutants associated with respiratory distress syndrome. J. Biol. Chem., 281(14), 9791-9800.
382. Hayashi, H. and Sugiyama, Y. (2007) 4-phenylbutyrate enhances the cell surface expression and the transport capacity of wild-type and mutated bile salt export pumps. Hepatology, 45(6), 1506-1516.
383. Kim, A.J.; Shi, Y.; Austin, R.C. and Werstuck, G.H. (2005) Valproate protects cells from ER stress-induced lipid accumulation and apoptosis by inhibiting glycogen synthase kinase-3. J. Cell Sci., 118(Pt 1), 89-99.
384. Bevins, R.L. and Zimmer, S.G. (2005) It's about time: scheduling alters effect of histone deacetylase inhibitors on camptothecin-treated cells. Cancer Res., 65(15), 6957-6966.